47 results on '"Moschini, Marco"'
Search Results
2. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
- Author
-
Padua, Tiago Costa de, Moschini, Marco, Martini, Alberto, Pederzoli, Filippo, Nocera, Luigi, Marandino, Laura, Raggi, Daniele, Briganti, Alberto, Montorsi, Francesco, and Necchi, Andrea
- Subjects
- *
ANTIBODY-drug conjugates , *TRANSITIONAL cell carcinoma , *CLINICAL trials , *METASTASIS , *ADVERSE health care events , *BLADDER cancer - Abstract
Introduction: Metastatic urothelial cancer (mUC) is an aggressive disease with limited overall survival and treatment options. Antibody-drug conjugates (ADCs) were designed with the intent to deliver potent cytotoxic drugs selectively to antigen-expressing tumor cells by linking cytotoxins to monoclonal antibodies (mAbs) and have emerged as new treatment options in mUC, mainly in chemotherapy (CT) and immune-checkpoint inhibitors (ICI)-exposed patients. We aimed to perform a scoping review to assess activity, efficacy, treatment-related adverse events (TRAEs), and impact on quality of life of ADCs in mUC.Methods: A review of the literature was performed in January 2022 using Pubmed and Embase databases according to the recommendations of the Joanna Briggs Institute. The search method involved querying for the terms "bladder carcinoma" or "urothelial carcinoma" with any of the following: "enfortumab vedotin" (EV), "sacituzumab govitecan" (SG), antibody-drug conjugate. Only prospective clinical trials were included.Results: Ultimately, eleven clinical trials with 1417 patients were selected for inclusion, and five drugs were identified: enfortumab vedotin (EV), sacituzumab govitecan (SG), disitamab vedotin (RC48-ADC), ASG-15ME (anti-SLITRK6), and trastuzumab deruxtecan. The different ADCs have been tested mainly in phase 1 or phase 2 trials, as monotherapy or in combination with ICI. Response rate ranged from 27% with SG in previously treated patients to 73.3% with EV plus pembrolizumab in cisplatin-ineligible patients as first-line treatment. The phase 3 trial, EV-301, confirmed EV superiority over investigator-chosen CT after failure to platinum-based CT and ICI, improving overall survival (12.88 vs. 8.97 months; HR 0.70; 95% CI, 0.56-0.89; P=0.001). TRAEs of any grade occurred in more than 90% of patients in phase 2 or 3 trials, with high rates of grade 3 ≥ events ranging from 51.4 to 73.5% in different trials. TRAEs of particular interest related to EV were rash, neuropathy, and hyperglycemia. SG was associated with diarrhea and hematologic toxicity. Data from phase 2 and 3 trials of EV suggest no impact on quality of life but an improvement in pain symptoms compared to the control arm.Conclusions: ACDs represent a new therapeutic option for the treatment of mUC. Level-1 evidence has already been achieved by EV in the post-CT and post-ICI settings. A high incidence of potential adverse events was observed in phase 2 and 3 trials, including rash, neutropenia, hematologic toxicity, and neuropathy. Clinicians should be aware of possible adverse events and their optimal management. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy.
- Author
-
Moschini, Marco, Dell’Oglio, Paolo, Luciano’, Roberta, Gandaglia, Giorgio, Soria, Francesco, Mattei, Agostino, Klatte, Tobias, Damiano, Rocco, Shariat, Shahrokh F., Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, Gallina, Andrea, Dell'Oglio, Paolo, and Luciano', Roberta
- Subjects
- *
BLADDER cancer treatment , *CYSTECTOMY , *CANCER-related mortality , *HISTOLOGY , *SURVIVAL analysis (Biometry) , *TREATMENT effectiveness , *DISEASE incidence ,BLADDER tumors - Abstract
Introduction: We sought to describe incidence of histological variants after radical cystectomy (RC) due to bladder cancer (BCa). Moreover, we investigated survival outcomes accounting for this parameter.Methods: We retrospectively evaluated data from 1,067 patients with BCa treated with RC between 1990 and 2013 at a single tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the effect of different histopathological variant on recurrence, cancer-specific mortality (CSM), and overall mortality (OM) after accounting for all available confounders.Results: Of 1,067 patients, 729 (68.3%) harbored pure urothelial BCa while 338 (31.7%) were found to have a variant. Considering uncommon variants, 21 (2.0%) were sarcomatoid, 10 (0.9%) lymphoepitelial, 19 (1.8%) small cell, 109 (10.2%) squamous, 89 (8.3%) micropapillary, 23 (2.2%) glandular, 34 (3.2%) mixed variants, and 33 (3.1%) were found with other types of variants. With a median follow-up of 6.2 years, 343 recurrence, 365 CSM, and 451 OM were recorded, respectively. At multivariable Cox regression analyses, the presence of small cell variant was associated with higher recurrence (hazard ratio [HR] = 3.47, P<0.001), CSM (HR = 3.30, P<0.04), and OM (HR = 2.97, P<0.003) as compared with pure urothelial cancer. Conversely, no survival differences were recorded considering other histological variants (all P> 0.1).Conclusion: Our study confirms that histological variant is not an infrequent event at RC specimen. However, in our single-center series, only patients found with small cell variant were associated with a negative effect on survival after RC. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
4. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
- Author
-
Tully, Karl H., Moschini, Marco, von Rundstedt, Friedrich-Carl E., Aziz, Atiqullah, Kluth, Luis A., Necchi, Andrea, Rink, Michael, Hendricksen, Kees, Sargos, Paul, Vetterlein, Malte W., Seiler, Roland, Poyet, Cedric, Krajewski, Wojciech, Fajkovic, Harun, Shariat, Shahrokh F., Xylinas, Evanguelos, and Roghmann, Florian
- Subjects
- *
BLADDER cancer , *PROPORTIONAL hazards models , *BLADDER obstruction , *PROGRESSION-free survival - Abstract
Purpose: To examine survival rates and to calculate the risk of disease recurrence, progression, overall, and cancer-specific mortality in patients diagnosed with high-risk NMIBC using a multi-institutional dataset to evaluate differences between the guidelines of the European Association of Urology and the guidelines of the National Comprehensive Cancer Network (NCCN) with regard to tumor size in risk stratification.Methods and Material: In total 1,116 individuals diagnosed with high-risk NMIBC between 2001 and 2013 were included in the analysis. Patients were stratified to NCCN guideline recommendations (high-grade T1, high-grade Ta ≤ 3 cm, and high-grade Ta > 3 cm). Recurrence and progression rates were calculated. Kaplan-Meier curves were fitted to examine differences in recurrence-free (RFS) and progression-free survival (PFS). Multivariable Cox proportional hazards regression models were employed to calculate differences in the RFS, PFS, overall, and cancer-specific survival (CSS).Results: The majority of patients were diagnosed with high-grade T1 disease (N = 576, 51.6%), while 34.2% and 14.2% of patients were diagnosed with high-grade Ta ≤ 3 cm and Ta > 3 cm NMIBC, respectively. The 1- and 5-year RFS (1-year: 80.5% vs. 64.9%; 5-year: 58.6% vs. 48.3%, P = 0.048) and PFS (1-year: 99.1% vs. 98.6%; 5-year: 97.7% vs. 92.4%, P = 0.054) rates were higher in patients with Ta ≤ 3 cm. Patients diagnosed with high-grade Ta > 3 cm experienced unfavorable progression-free, and cancer-specific survival compared to high-grade Ta ≤ 3 cm, respectively (PFS: 2.41, 95% confidence interval [CI] 1.05-5.56, P = 0.038; CSS: hazard ratios [HR] 2.22, 95% CI 1.02-4.89, P = 0.048).Conclusion: Patients diagnosed with high-grade Ta NMIBC ≤3 cm demonstrated a favorable progression-free, and cancer-specific survival compared to patients diagnosed with high-grade Ta > 3 cm and high-grade T1 NMIBC. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy.
- Author
-
Moschini, Marco, Soria, Francesco, Mathieu, Romain, Xylinas, Evanguelos, D'Andrea, David, Tan, Wei Shen, Kelly, John D., Simone, Giuseppe, Tuderti, Gabriele, Meraney, Anoop, Krishna, Suprita, Konety, Badrianath, Zamboni, Stefania, Baumeister, Philipp, Mattei, Agostino, Briganti, Alberto, Montorsi, Francesco, Galucci, Michele, Rink, Michael, and Karakiewicz, Pierre I.
- Subjects
- *
SURGICAL site , *CYSTECTOMY , *LOGISTIC regression analysis , *CYSTOTOMY , *LENGTH of stay in hospitals , *RESEARCH , *BLADDER , *SURGICAL robots , *RESEARCH methodology , *SURGICAL complications , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *TRANSITIONAL cell carcinoma , *TREATMENT effectiveness , *COMPARATIVE studies , *COMBINED modality therapy , *PROBABILITY theory , *LONGITUDINAL method , *SURGICAL excision , *LYMPH node surgery ,BLADDER tumors - Abstract
Introduction: The use of robotic-assisted radical cystectomy (RARC) is becoming more widespread. While its safety is accepted, its oncological efficacy as compared to the current standard, open radical cystectomy (ORC), remains debatable.Materials and Methods: The aim of this study is to compare the rates of positive soft tissue surgical margins (STSM), between patients treated with RARC or ORC, using a large contemporaneous collaborative database. We included 2,536 patients with urothelial carcinoma of the bladder treated at 26 institutions. A propensity-score matching 1:1 was performed with 3 ORC patients matched to 1 RARC patient. The final cohort included 1,614 patients. Uni- and multivariable logistic regression analyses tested the impact of surgical technique on STSM status, before and after propensity-score matching.Results: Overall, 870 (34%) patients underwent RARC and 1,666 (66%) ORC. The overall STSM rate was 11%; 10% in the ORC group and 13% in the RARC group. Within the propensity-score-matched cohort, the positive STSM rate were 14% and 13% in the ORC and RARC group, respectively (P = 0.1). In multivariable analysis, after propensity match RARC approach was not associated with the risk of a positive STSM (P = 0.1). These results were confirmed in the subgroup of patients with pathologic non-organ-confined or organ-confined diseases.Conclusions: While treatment with RARC is associated with a higher absolute rate of STSM, the difference did not remain after adjustment for the effects of other established prognostic factors. Results from ongoing trials are awaited to assess the validity of these findings. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy.
- Author
-
Moschini, Marco, Shariat, Shahrokh F., Abufaraj, Mohammad, Foerster, Beat, D′Andrea, David, Soria, Francesco, Dell′Oglio, Paolo, Mattei, Agostino, Montorsi, Francesco, Colombo, Renzo, Briganti, Alberto, Gallina, Andrea, D Andrea, David, and Dell Oglio, Paolo
- Subjects
- *
BLADDER cancer patients , *CYSTECTOMY , *CANCER radiotherapy , *REGRESSION analysis , *METASTASIS , *CANCER relapse , *COMPARATIVE studies , *LONGITUDINAL method , *LYMPH nodes , *RESEARCH methodology , *MEDICAL cooperation , *HEALTH outcome assessment , *PROGNOSIS , *RADIOTHERAPY , *RESEARCH , *EVALUATION research , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator ,BLADDER tumors - Abstract
Objective: To evaluate incidence and predictors of local failure (LF) after radical cystectomy (RC) due to bladder cancer.Methods: We focused on 1,112 patients treated with RC, between 1990 and 2012, at a single center. LF was defined as imaging evidence of recurrence in the pelvic soft tissues or nodes below the aortic bifurcation at least 3 months before the detection of distant metastases. Competing risk analyses tested the relationship between clinical and pathological factors and the risk to develop LF. Regression tree analysis stratified patients into risk-groups based on their characteristics and the corresponding LF rate.Results: Overall, 50 (4.5%) patients developed LF during a median follow-up period of 62 (35-92) months. On univariable competing risk regression analyses, pathological T stage (pT4 vs. pT3; hazard ratio [HR] = 2.55, P = 0.003), soft tissue surgical margin (STSM; HR = 2.95, P = 0.005), and variant histology (HR = 1.79, P = 0.03) were associated with an increased risk of developing LF. The cohort was stratified into 4 risk groups: very low (≤pT3a disease and pure urothelial histology), low (≤pT3a disease and variant histology), intermediate (pT4 disease), and high (positive STSM).Conclusions: LF is an important event in RC patients. We developed a new risk model based on bladder cancer characteristics. Our findings could help with the identification of the best candidate for consideration of adjuvant radiotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.
- Author
-
Moschini, Marco, Shariat, Shahrokh F., Freschi, Massimo, Soria, Francesco, D’Andrea, David, Abufaraj, Mohammad, Foerster, Beat, Dell’Oglio, Paolo, Zaffuto, Emanuele, Mattei, Agostino, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Gallina, Andrea, Colombo, Renzo, D'Andrea, David, and Dell'Oglio, Paolo
- Subjects
- *
BLADDER cancer treatment , *TRANSURETHRAL prostatectomy , *CYSTECTOMY , *BLADDER cancer diagnosis , *LOGISTIC regression analysis , *HEALTH outcome assessment , *RETROSPECTIVE studies , *TRANSITIONAL cell carcinoma , *DIAGNOSIS ,BLADDER tumors - Abstract
Introduction: To evaluate incidence of histological variants and grade agreement between transurethral resection (TUR) and radical cystectomy (RC) in patients with bladder cancer.Methods: A total of 779 patients treated with TUR and subsequently with RC between 1990 and 2013 at a single center were analyzed retrospectively. Variant histology classifications used in our analyses were sarcomatoid, small cell, squamous, or micropapillary. Grade agreement was calculated using the Cohen kappa coefficient. Logistic regression analyses were built to predict adverse pathologic features from histological variants at TUR.Results: Considering TUR, 213 (27.3%) patients were diagnosed with histological variants. Of these, 2.1% (n = 16) were found with sarcomatoid variant, 1.7% (n = 13) with small cell, 7.1% (n = 55) with squamous, 12.5% (n = 97) with micropapillary. Considering RC, 212 (27.2%) patients were diagnosed with histological variants. Poor agreement was found considering micropapillary variant and the presence of a histological variant in general (0.11 and 0.27, respectively). Intermediate agreement was found analyzing the presence of sarcomatoid, small cell, and squamous variants (0.43, 0.61, and 0.61, respectively). Small cell carcinoma at TUR was found associated with an increased risk of harboring positive soft tissue surgical margin (odds ratio = 2.08; CI: 1.27-3.41; P = 0.03).Conclusions: One out of our patients with bladder cancer was diagnosed with a histological variant either at TUR and RC. We found poor agreement between TUR and RC. Our findings highlight that TUR alone is not sufficient to accurately evaluate the presence of histological variants that may have an effect on treatment and survival outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.
- Author
-
Moschini, Marco, Shariat, Shahrokh F., Abufaraj, Mohammad, Soria, Francesco, Klatte, Tobias, Croce, Giovanni La, Mattei, Agostino, Damiano, Rocco, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, and Gallina, Andrea
- Subjects
- *
BLADDER cancer treatment , *CYSTECTOMY , *CANCER relapse , *DISEASE incidence , *REGRESSION analysis , *FOLLOW-up studies (Medicine) , *SURGICAL excision , *LONGITUDINAL method , *LYMPH node surgery , *PROGNOSIS , *SURVIVAL , *RETROSPECTIVE studies , *CARCINOMA in situ , *DIAGNOSIS ,BLADDER tumors - Abstract
Introduction: To evaluate the incidence of carcinoma in situ (CIS) in patients treated with radical cystectomy (RC) due to bladder cancer and to assess its effect on recurrence and survival rates.Methods: The study focused on 1,128 consecutive nonmetastatic patients with bladder cancer treated with RC at a single tertiary care referral center from 1994 to 2014. The Kaplan-Meier method was used to compare recurrence, cancer-specific mortality (CSM), and overall mortality-free rates in the overall population and in pT0-pT2 and pT3-pT4 patients after stratifying according to the presence of CIS. Multivariable (MVA) Cox regression analyses tested the effect of the presence of CIS on survival outcomes. MVA competing risk analyses were performed to assess the effect of CIS on urothelial recurrence.Results: The presence of CIS was reported in 277 (24.6%) patients. During a median follow-up of 6 years, 355 recurrences, 377 CSM, and 468 overall mortality were reported. At MVA Cox regression analyses, the presence of concomitant CIS was not associated with any survival effect when the overall population was considered (all P≥0.3). At MVA Cox regression analyses, there was no effect of CIS on survival outcomes in pT3-pT4 patients (all P>0.2); on the contrary, the presence of CIS was associated with worse CSM in pT0-pT2 patients only (hazard ratio [HR] = 1.82; CI: 1.01-3.29; P = 0.04). At MVA competing risk analyses predicting urothelial recurrence only, the presence of CIS was associated to an increased risk of urothelial recurrence in pT0-pT2 patients (HR = 2.99; CI: 1.05-8.53; P = 0.04), pT3-pT4 patients (HR = 10.29; CI: 1.40-75.75; P = 0.02), and in the overall population (HR = 4.47; CI: 1.81-11.07; P = 0.001).Conclusion: An increased risk of developing urothelial recurrence only was recorded in patients diagnosed with CIS at RC. Physicians should consider this aspect ensuring a more severe follow-up schemes in patients who harbored this pathological feature. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
9. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer.
- Author
-
Soria, Francesco, Moschini, Marco, Haitel, Andrea, Wirth, Gregory J., Gust, Kilian M., Briganti, Alberto, Rouprêt, Morgan, Klatte, Tobias, Hassler, Melanie R., Karakiewicz, Pierre I., and Shariat, Shahrokh F.
- Subjects
- *
BLADDER cancer , *GENETIC overexpression , *HER2 protein , *CYSTECTOMY , *IMMUNOHISTOCHEMISTRY , *ANTINEOPLASTIC agents , *PROTEIN analysis , *CANCER relapse , *CANCER invasiveness , *CELL receptors , *COMBINED modality therapy , *COMPARATIVE studies , *GENES , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROTEINS , *RESEARCH , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TRANSITIONAL cell carcinoma , *KAPLAN-Meier estimator , *TUMOR treatment , *THERAPEUTICS ,BLADDER tumors - Abstract
Purpose: The aim of this study was to evaluate the overexpression of human epidermal growth factor receptor 2 (HER2) in patients with bladder cancer (BCa) and to assess its association with oncological outcomes.Methods: This retrospective single-center study included 354 patients with BCa treated with radical cystectomy (RC). HER2 status was assessed with immunohistochemistry and scored according to HercepTest. Conditional survival and competing risk regression were performed to assess the association between HER2 expression and survival outcomes.Results: HER2 was overexpressed in 36% of patients. HER2 overexpression was associated with features of tumor aggressiveness such as lymph-node metastases (P = 0.002). At a median follow-up of 123 months (interquartile range: 79-180), 160 patients (45%) experienced disease recurrence, 263 patients (74%) died and 157 (44%) died of cancer. On multivariable analyses, HER2 overexpression was not significantly associated with any oncological outcomes. Adding HER2 status to a model for the prediction of survival outcomes did not change the accuracy of the model for any of the outcomes. Interestingly, HER2 status significantly affected late disease recurrence (P = 0.05 for conditional survival at 24 months).Conclusions: More than one third of RC patients overexpress HER2 in their tumors. HER2 overexpression was associated with features of biological and clinical aggressiveness. HER2 did not add prognostic significance to the standard established predictors of survival outcomes after RC. However, due to the high overexpression rate, it could represent a target for therapy in select advanced BCa tumors. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution.
- Author
-
Moschini, Marco, Bianchi, Marco, Rossi, Martina Sofia, Dell׳Oglio, Paolo, Gandaglia, Giorgio, Fossati, Nicola, Mattei, Agostino, Damiano, Rocco, Shariat, Shahrokh F., Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, and Gallina, Andrea
- Subjects
- *
BLADDER cancer treatment , *BLOOD transfusion , *ABO blood group system , *CYSTECTOMY , *REGRESSION analysis , *RH factor , *TIME , *KAPLAN-Meier estimator , *TUMOR treatment ,BLADDER tumors - Abstract
Introduction and Objectives: Perioperative transfusions have been recently associated to poor outcomes as an indirect consequence of immune-hematological changes related to transfusion itself and blood type. We tested the role of blood transfusion on cancer-specific mortality (CSM) and overall mortality (OM), considering the effect of ABO system, Rh factor, and timing of transfusions.Materials and Methods: The study focused on 728 patients with bladder cancer treated with radical cystectomy at a single tertiary care referral center between January 1995 and August 2013 with complete ABO blood type information. Kaplan-Meier analysis was used to assess the effect of transfusions, stratified according to ABO type and Rh factor, on CSM and OM. The same endpoints were tested in Cox regression models, after adjusting for all available confounders.Results: A total of 341 (46.8%), 277 (38.0%), 83 (11.4%), and 27 (3.7%) patients had blood type O, A, B and AB, respectively. Overall, 630 (86.5%) and 98 (13.5%) patients were Rh-and Rh+, respectively. At a median follow-up time of 65 months, 225 (30.9%) and 282 (38.7%) patients recorded CSM and OM, respectively. At univariable analyses, ABO blood type and Rh status were not associated to either CSM or OM (all P>0.2). Similar results were observed when ABO blood type and Rh factor were tested in multivariable models (all P>0.3). Conversely, Charlson score, preoperative hemoglobin, number of nodes removed, pathological T stage, and number of positive nodes were associated to both CSM and OM (all P<0.05). Interestingly, intraoperative transfusion (all P<0.03) but not the administration of blood units in the postoperative period (P>0.05) was associated with an increase of CSM and OM.Conclusions: Although ABO type or Rh factor or both were associated with several adverse outcomes in many cancers, we were not able to confirm this association in bladder cancer. Based on our results, the effect of transfusion on survival is independent by ABO type but is associated to the timing of blood supply administration. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
11. Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy.
- Author
-
Moschini, Marco, Gallina, Andrea, Freschi, Massimo, Luzzago, Stefano, Fossati, Nicola, Gandaglia, Giorgio, Dell׳oglio, Paolo, Damiano, Rocco, Serretta, Vincenzo, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, and Dell'oglio, Paolo
- Subjects
- *
POSTOPERATIVE care , *CYSTECTOMY , *INTRAOPERATIVE care , *CANCER-related mortality , *LOGISTIC regression analysis , *POSTOPERATIVE period , *SURVIVAL analysis (Biometry) , *RETROSPECTIVE studies ,URETER tumors - Abstract
Background: Despite several studies, the adequate management of positive distal ureter margins at the time of radical cystectomy (RC) remains controversial. Particularly, it is not clear whether the achievement of negative distal ureter margins at the intraoperative frozen sections (IFS) affects postoperative cancer-specific mortality (CSM).Methods: In all, 1,447 consecutive patients treated with RC at a single center between January 1987 and August 2014 were considered. Multivariable (MVA) logistic regression analyses were used to determine predictors of positive IFS. MVA Cox regression analyses were used to test the effect on CSM of intraoperative conversion to negative margins.Results: At IFS, 368 patients (25%) experienced at least 1 positive margin. Of these, a negative conversion of the margin at IFS occurred in 178 (48%) whereas 190 (52%) had a positive final ureteral margin. The mean follow-up was 95 months (median = 102). At MVA, history of carcinoma in situ (odds ratio = 6.40, P<0.001) was predictors of positive margin at IFS. At MVA, ureteral margins that were not converted to negative (hazard ratio = 1.92, P = 0.01) were associated with CSM but only in patients with negative soft tissue margin and without node metastases.Conclusions: Achieving negative IFS margins may be associated with survival benefit in patients without residual bladder cancer after RC. Patients who recorded a history of carcinoma in situ before RC are at higher risk to incur positive ureteral margin at IFS and should be investigated during RC. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
12. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer.
- Author
-
Soria, Francesco, Lucca, Ilaria, Moschini, Marco, Mathieu, Romain, Rouprêt, Morgan, Karakiewicz, Pierre I., Briganti, Alberto, Rink, Michael, Gust, Kilian M., Hassler, Melanie R., Foerster, Beat, Abufarraj, Mohammad, Haitel, Andrea, Klatte, Tobias, and Shariat, Shahrokh F.
- Subjects
- *
BLADDER cancer treatment , *BLADDER cancer , *CAVEOLINS , *CANCER relapse , *SURVIVAL analysis (Biometry) , *PROGNOSIS , *CARRIER proteins , *DISEASE relapse , *TREATMENT effectiveness , *CYSTECTOMY ,BLADDER tumors - Abstract
Purpose: Overexpression of Caveolin-1 has been associated with cancer growth, migration, and metastases in several malignancies, but only few data are available on its role in bladder cancer (BCa). The aim of this study is to validate Caveolin-1 as a prognosticator of recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) in a large cohort of patients treated with radical cystectomy (RC) for BCa.Methods: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray from 424 patients treated with RC for UCB at a single institution. Caveolin-1 was considered overexpressed when at least 50% of the tumor cells stained positively. Univariable and multivariable Cox proportional hazards regression models were used to assess the association of Caveolin-1 expression with RFS, OS, and CSS.Results: Overexpression of Caveolin-1 was observed in 116 (27.4%) patients and was associated with lymph node metastasis (P = 0.003). Median follow-up for patients alive at last follow-up was 129 months (interquartile range [IQR]: 82-178). Patients with overexpression of Caveolin-1 had significant worse RFS, OS, and CSS compared to those with normal expression (log-rank test, P = 0.008, P = 0.001, and P = 0.005, respectively). At multivariable analyses that adjusted for the effects of standard clinicopathologic features, Caveolin-1 remained associated with OS (hazard ratio = 1.47, P = 0.002) and CSS (hazard ratio = 1.42, P = 0.03). Conversely, no association with RFS was found (P = 0.1). Addition of Caveolin-1 in a model for prediction of survival did not improve the accuracy of the prognostic model. Actually, C-index did not differ among models with or without Caveolin-1 (0.72 for a model predicting RFS, 0.65 for OS, and 0.71 for CSS).Conclusions: Caveolin-1 is overexpressed in one-third of patients with BCa treated with RC. Overexpression of Caveolin-1 is significantly associated with OS and CSS, but not with RFS, in patients with BCa treated with RC. However, it is not clinically useful as it does not improve upon the predictive accuracy of survival achieved by pathologic variables alone. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362.
- Author
-
Soria, Francesco, Lucca, Ilaria, Moschini, Marco, Mathieu, Romain, Rouprêt, Morgan, Karakiewicz, Pierre I, Briganti, Alberto, Rink, Michael, Gust, Kilian M, Hassler, Melanie R, Foerster, Beat, Abufarraj, Mohammad, Haitel, Andrea, Klatte, Tobias, and Shariat, Shahrokh F
- Published
- 2022
- Full Text
- View/download PDF
14. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis.
- Author
-
Stangl-Kremser, Judith, Muto, Gianluca, Grosso, Antonio Andrea, Briganti, Alberto, Comperat, Eva, Di Maida, Fabrizio, Montironi, Rodolfo, Remzi, Mesut, Pradere, Benjamin, Soria, Francesco, Albisinni, Simone, Roupret, Morgan, Shariat, Shahrokh Francois, Minervini, Andrea, Teoh, Jeremy Yuen-Chun, Moschini, Marco, Cimadamore, Alessia, Mari, Andrea, and European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
- Subjects
- *
META-analysis , *SYSTEMATIC reviews , *RETROSPECTIVE studies , *PROGNOSIS , *CANCER relapse , *TRANSITIONAL cell carcinoma ,BLADDER tumors ,URETER tumors - Abstract
Patients with upper tract urothelial carcinoma (UTUC) often have a delayed diagnosis and by then, present with advanced disease which has been shown to be associated with lymphovascular invasion (LVI). It has been suggested to be involved in the metastatic cascade of the disease. In this review, we provide an extensive up-to-date summary of the current knowledge about the prognostic impact of LVI in patients undergoing radical nephroureterectomy (RNU). A systematic search of PubMed/MEDLINE, Scopus, EMBASE, and Web of Science for all reports published from 2010 through 2021 was performed. We performed pooled analyses of hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) of series that evaluated LVI as a prognostic factor in adults with UTUC who underwent RNU. The assessed oncological outcomes were disease recurrence, cancer-specific and overall survival. A meta-regression analysis was used to explore potential heterogeneity. A total of 58 series met the eligibility criteria for qualitative and quantitative synthesis. We included 29,829 patients, ranging from 101 to 2492 per study. All series were retrospective. LVI was present in 7,818 patients (26.2%). The median age of the patients was 69 years and the median follow-up was 40 months. In 40 of 58 studies (68.9%), adjuvant chemotherapy was given. The pooled HRs show that LVI predicts a greater risk of recurrence of the disease (pooled HR 1.43, 95% CI: 1.31-1.55, P = 0.000; I2 = 76.3%), and decreases cancer-specific survival (pooled HR 1.53, 95% CI: 1.41-1.66, P = 0.000; I2 = 72.3%) and overall survival (HR 1.56, 95% CI 1.45-1.69, P = 0.000; I2 = 62.9%). It can be concluded that LVI is a common histologic pattern in surgical specimen in patients undergoing RNU for UTUC. LVI predicts a greater risk of recurrence and mortality, thus it should be carefully assessed in clinical practice to determine prognosis, and for optimal decision-making within the concept of personalized therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis.
- Author
-
Laukhtina, Ekaterina, Mori, Keiichiro, D'Andrea, David, Moschini, Marco, Abufaraj, Mohammad, Soria, Francesco, Mari, Andrea, Krajewski, Wojciech, Albisinni, Simone, Teoh, Jeremy Yuen-Chun, Quhal, Fahad, Sari Motlagh, Reza, Mostafaei, Hadi, Katayama, Satoshi, Grossmann, Nico С., Rajwa, Pawel, Enikeev, Dmitry, Zimmermann, Kristin, Fajkovic, Harun, and Glybochko, Petr
- Subjects
- *
BLADDER cancer , *SURVIVAL rate , *CYSTECTOMY , *TREATMENT effectiveness , *SURVIVAL analysis (Biometry) , *WOMEN patients , *META-analysis , *SYSTEMATIC reviews , *CANCER relapse , *DISEASE incidence ,BLADDER tumors - Abstract
We aimed to conduct a systematic review and meta-analysis assessing the incidence and risk factors of urethral recurrence (UR) as well as summarizing data on survival outcomes in patients with UR after radical cystectomy (RC) for bladder cancer. The MEDLINE and EMBASE databases were searched in February 2021 for studies of patients with UR after RC. Incidence and risk factors of UR were the primary endpoints. The secondary endpoint was survival outcomes in patients who experienced UR. Twenty-one studies, comprising 9,435 patients, were included in the quantitative synthesis. Orthotopic neobladder (ONB) diversion was associated with a decreased probability of UR compared to non-ONB (pooled OR: 0.44, 95% CI: 0.31-0.61, P < 0.001) and male patients had a significantly higher risk of UR compared to female patients (pooled OR: 3.16, 95% CI: 1.83-5.47, P < 0.001). Among risk factors, prostatic urethral or prostatic stromal involvement (pooled HR: 5.44, 95% CI: 3.58-8.26, P < 0.001; pooled HR: 5.90, 95% CI: 1.82-19.17, P = 0.003, respectively) and tumor multifocality (pooled HR: 2.97, 95% CI: 2.05-4.29, P < 0.001) were associated with worse urethral recurrence-free survival. Neither tumor stage (P = 0.63) nor CIS (P = 0.72) were associated with worse urethral recurrence-free survival. Patients with UR had a 5-year CSS that varied from 47% to 63% and an OS - from 40% to 74%; UR did not appear to be related to worse survival outcomes. Male patients treated with non-ONB diversion as well as patients with prostatic involvement and tumor multifocality seem to be at the highest risk of UR after RC. Risk-adjusted standardized surveillance protocols should be developed into clinical practice after RC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review.
- Author
-
Laukhtina, Ekaterina, Pradere, Benjamin, Mori, Keiichiro, Schuettfort, Victor M., Quhal, Fahad, Mostafaei, Hadi, Sari Motlagh, Reza, Aydh, Abdulmajeed, Moschini, Marco, Enikeev, Dmitry, Karakiewicz, Pierre I., Abufaraj, Mohammad, Shariat, Shahrokh F., and European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
- Subjects
- *
PROGNOSIS , *NEOADJUVANT chemotherapy , *TRANSITIONAL cell carcinoma , *MYELOID-derived suppressor cells , *NEUTROPHIL lymphocyte ratio , *THERAPEUTIC use of antineoplastic agents , *SYSTEMATIC reviews , *COMBINED modality therapy ,BLADDER tumors - Abstract
Purpose: The present systematic review aimed to identify prognostic values of blood-based biomarkers in patients treated with neoadjuvant chemotherapy (NAC) for urothelial carcinoma of the bladder (UCB).Material and Methods: The PubMed, Web of Science, and Scopus databases were searched in August 2020 according to the PRISMA statement. Studies were deemed eligible if they compared oncological outcomes in patients treated with NAC for UCB with and without pretreatment laboratory abnormalities.Results: Overall, ten studies, including 966 patients who underwent NAC, met our eligibility criteria. Six studies provided data on pretreatment neutrophil to lymphocyte ratio (NLR) with contradicting results on its association with pathologic response (PR) and complete pathologic response (pCR); some studies reported a strong association between a high level of pretreatment NLR and worse survival outcomes. Two studies reported that higher pretreatment platelet-lymphocyte ratio (PLR) is associated with a lower likelihood of achieving PR and/or pCR, while lymphocyte count alone had the opposite association. One study reported a negative association between pretreatment blood-based myeloid-derived suppressors cells and pCR. Patients who experienced a remission have been reported to have higher level of lymphocyte subsets (CD3+, CD4+, CD57+ cells, the ratio of CD4+/CD8+) compared to those who had progression. One study found that low pretreatment blood-based human chorionic gonadotrophin b subunit (hCGβ) was associated with improved overall survival (OS). High levels of epithelial tumor markers (CA-125, CA 19-9) were also associated with worse OS and recurrence-free survival in the NAC setting.Conclusion: Current evidence suggests that several readily available, easy measurable blood-based biomarkers hold promise to improve our selection of UCB patients who are likely benefit from NAC. However, their role as an adjunct to established histopathologic characteristics for clinical decision-making requires further validation along the biomarker phased approach. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
- Author
-
Laukhtina, Ekaterina, Pradere, Benjamin, Mori, Keiichiro, Schuettfort, Victor M., Quhal, Fahad, Mostafaei, Hadi, Sari Motlangh, Reza, Katayama, Satoshi, Grossmann, Nico C., Moschini, Marco, Enikeev, Dmitry, Shariat, Shahrokh F., and European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
- Subjects
- *
PROGNOSIS , *TRANSITIONAL cell carcinoma , *GENES , *DNA repair , *GENE expression - Abstract
Purpose: The present systematic review aimed to identify prognostic values of tissue-based biomarkers in patients treated with neoadjuvant systemic therapy (NAST), including chemotherapy (NAC) and checkpoint inhibitors (NAI) for urothelial carcinoma of the bladder (UCB).Material and Methods: The PubMed, Web of Science, and Scopus databases were searched in August 2020 according to the PRISMA statement. Studies were deemed eligible if they compared oncologic or pathologic outcomes in patients treated with NAST for UCB with and without detected pretreatment tissue-based biomarkers.Results: Overall, 44 studies met our eligibility criteria. Twenty-three studies used immunohistochemistry (IHC), 19 - gene expression analysis, three - quantitative polymerase chain reaction (QT PCR), and two - next-generation sequencing (NGS). According to the currently available literature, predictive IHC-assessed biomarkers, such as receptor tyrosine kinases and DNA repair pathway alterations, do not seem to convincingly improve our prediction of pathologic response and oncologic outcomes after NAC. Luminal and basal tumor subtypes based on gene expression analysis showed better NAC response, while claudin-low and luminal-infiltrated tumor subtypes did not. In terms of NAI, PD-L1 seems to maintain value as a predictive biomarker, while the utility of both tumor mutational burden and molecular subtypes remains controversial. Specific genomic alterations in DNA repair genes have been shown to provide significant predictive value in patient treated with NAC. QT PCR quantification of specific genes selected through microarray analysis seems to classify cases regarding their NAC response.Conclusion: We believe that the present systematic review may offer a robust framework that will enable the testing and validation of predictive biomarkers in future prospective clinical trials. NGS has expanded the discovery of molecular markers that are reflective of the mechanisms of the NAST response. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?
- Author
-
Soria, Francesco, D'Andrea, David, Moschini, Marco, Giordano, Andrea, Mazzoli, Simone, Pizzuto, Giuseppe, Hurle, Rodolfo, Colombo, Renzo, Briganti, Alberto, Altieri, Vincenzo, Shariat, Shahrokh F., and Gontero, Paolo
- Subjects
- *
DECISION making , *BLADDER , *CARCINOMA in situ , *BLADDER cancer , *PATIENT selection , *URETHRAL cancer , *URETHRA diseases , *CYSTECTOMY , *URETHRA , *RESEARCH , *PREDICTIVE tests , *CARCINOGENESIS , *RESEARCH methodology , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *TUMOR classification , *COMPARATIVE studies , *REOPERATION ,BLADDER tumors - Abstract
Purpose: To evaluate the predictive factors of pT0 at repeated transurethral resection of the bladder (re-TURB) in pT1 high-grade (HG) nonmuscle invasive bladder cancer in order to explore the possibility to avoid it in well-selected patients.Methods: This multicenter retrospective study included patients with pT1HG nonmuscle invasive bladder cancer from 4 different centers who underwent a complete TURB. Re-TURB was defined as a second resection which involved the site of the first TURB performed within 2-6 weeks from the previous resection. A multivariable logistic-regression model was performed to evaluate the predictors of pT0 at re-TURB. A nomogram was built to calculate the probability of obtaining a negative histology at re-TURB. The performance of the nomogram and its net benefit were tested with the decision curve analysis.Results: Overall, 321 patients were included in the study. On multivariable logistic regression, detrusor muscle in the specimen (HR 1.99, P = 0.02), concomitant carcinoma in situ (HR 0.29, P = 0.005) and resection performed with en-bloc technique (HR 7.71, P = 0.01) were independent predictors of pT0 at re-TURB. Decision curve analysis showed a net benefit for the nomogram for each probability over 0.35 compared to the strategy to perform a re-TURB in all pT1HG tumors.Conclusions: The presence of detrusor muscle in TURB specimen, the absence of concomitant carcinoma in situ and the en-bloc resection were able to predict a negative histology at re-TURB, opening the door to the possibility to avoid it in an extremely well-selected cohort of patients. External validations and prospective studies are urgently needed. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study.
- Author
-
Ślusarczyk, Aleksander, Zapała, Piotr, Zapała, Łukasz, Rajwa, Paweł, Moschini, Marco, Laukhtina, Ekaterina, and Radziszewski, Piotr
- Subjects
- *
TRANSITIONAL cell carcinoma , *URINARY organs , *LYMPHADENECTOMY , *PROPENSITY score matching , *SURGICAL excision , *KIDNEY tumors - Abstract
• Oncologic outcomes following radical nephroureterectomy and segmental ureterectomy (SU) for advanced upper urinary tract urothelial cancer remain poor. • SU is a viable option even in patients with muscle-invasive upper urinary tract urothelial cancer. • Our population-based study suggests that SU provides noninferior cancer-specific survival compared to radical nephroureterectomy. Although kidney-sparing surgery (KSS) is a nonminor option for low-risk upper urinary tract urothelial cancer (UTUC), its oncological benefits in high-risk UTUC remain unclear when compared to radical nephroureterectomy (RNU). This study aimed to compare the oncological outcomes of RNU and KSS in patients with UTUC. We searched the SEER database for patients treated for primary non-metastatic UTUC with either RNU or a kidney-sparing approach (segmental ureterectomy (SU) or local tumor excision (LTE)) between 2004 and 2018. The study included 6,659 patients with primary non-metastatic UTUC treated with surgery; 2,888 (43.4%) and 3,771 (56.6%) patients presented with ureteral and renal pelvicalyceal tumors, respectively. Finally, 5,479 (82.3%) patients underwent RNU, 799 (12.0%) were treated with SU, and 381 (5.7%) patients received LTE. For confounder control, propensity score matching (PSM) of patients treated with SU and RNU was performed to adjust for T stage, grade, age, gender, tumor size, and lymphadenectomy performance. PSM analysis included 694 patients treated with RNU and 694 individuals who underwent SU. In multivariable Cox regression and Kaplan-Meier analyses, we found no difference in either CSS or OS between RNU and SU, even in the subgroup of high-grade and/or muscle-invasive UTUC including pT3-T4 tumors (all p > 0.05). In this population-based study, SU provides equivalent CSS and OS compared to RNU, even in high-risk and locally advanced ureteral cancer. Due to the unavoidable risk of selection bias, further prospective studies are expected to overcome the limitations of this study and support the wider implementation of KSS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Role of serum cholinesterase in patients treated with salvage radical prostatectomy.
- Author
-
Vartolomei, Mihai Dorin, D'Andrea, David, Chade, Daher C., Soria, Francesco, Kimura, Shoji, Foerster, Beat, Abufaraj, Mohammad, Mathieu, Romain, Moschini, Marco, Rouprêt, Morgan, Briganti, Alberto, Karakiewicz, Pierre I., and Shariat, Shahrokh F.
- Subjects
- *
PROSTATE cancer , *PROSTATECTOMY , *CHOLINE , *SERUM , *STUDY skills - Abstract
Background: Serum cholinesterase (ChE) a serine hydrolase that catalyses the hydrolysis of esters of choline, is involved in cellular proliferation and differentiation, therefore affecting carcinogenesis. The aim of this study was to understand the prognostic role of preoperative serum ChE in patients with radiation-recurrent prostate cancer (CaP) treated with salvage radical prostatectomy (SRP).Material and Methods: This retrospective study included 214 patients with radiation-recurrent CaP treated with SRP from January 2007 to December 2015 at 5 academic centers. Patients were considered with abnormal/decreased ChE levels if <5 kU/l. Biochemical recurrence-free and metastases-free (MFS) survival analyses were performed.Results: Median serum ChE level was 6.9 (interquartile range) 6-7.7) kU/l. Serum ChE level (<5 kU/l) was decreased in 25 (11.7%) patients. Decreased serum ChE level was associated with lower body mass index (P = 0.006) and metastasis to lymph nodes (P = 0.004). In multivariable analysis, continuous ChE was an independent predictor of MFS (hazard ratio [HR] 0.48, confidence interval [CI] 0.33-0.71, P < 0.001), overall survival (HR 0.68, CI 0.48-0.96, P = 0.03) and cancer-specific survival (HR 0.41, CI 0.2-0.84, P = 0.01). Serum ChE improved the C-index (by 2.54%) to 87.8% for prediction of overall survival and (by 3%) to 92% for prediction of MFS.Conclusion: Preoperative serum ChE is associated with the development of metastasis in patients with radiation-recurrent CaP who underwent SRP. The biological underpinning of this association with the biological and clinical aggressiveness of CaP needs to be further elucidated. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
- Author
-
Abufaraj, Mohammad, Shariat, Shahrokh F., Haitel, Andrea, Moschini, Marco, Foerster, Beat, Chłosta, Piotr, Gust, Kilian, Babjuk, Marek, Briganti, Alberto, Karakiewicz, Pierre I., and Albrecht, Walter
- Subjects
- *
CADHERINS , *BLADDER cancer patients , *TRANSURETHRAL prostatectomy , *IMMUNOHISTOCHEMISTRY , *CANCER invasiveness - Abstract
Purpose: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy.Patients and Methods: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. Multivariable Cox regression models were performed to evaluate the prognostic effect of N-cadherin on survival outcomes.Results: N-cadherin expression was observed in 333 patients (40.3%); it was associated with pT1 stage and high tumor grade (both were P<0.001). Median follow-up was 55 months (interquartile range: 18-106). On multivariable Cox regression analyses that adjusted for the effect of the standard clinicopathologic features, N-cadherin expression remained associated with recurrence-free survival (P = 0.007) but not progression-free survival (P = 0.3), cancer-specific survival (P = 0.2), or overall survival (P = 0.9). Adding N-cadherin to a model for prediction of disease recurrence modestly improved its discrimination from 72.8% to 73.4%.Conclusion: N-cadherin is expressed in approximately 2/5 patients with NMIBC. Its expression is associated with adverse pathological features and higher risk of disease recurrence but not progression. N-cadherin could be incorporated in predictive tools to assist in recurrence prediction helping thereby in patient selection regarding adjuvant therapies and follow-up planning. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
22. Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
- Author
-
Barletta, Francesco, Tappero, Stefano, Panunzio, Andrea, Incesu, Reha-Baris, Cano Garcia, Cristina, Piccinelli, Mattia Luca, Tian, Zhe, Gandaglia, Giorgio, Moschini, Marco, Terrone, Carlo, Antonelli, Alessandro, Tilki, Derya, Chun, Felix K.H., De Cobelli, Ottavio, Saad, Fred, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, and Karakiewicz, Pierre I.
- Subjects
- *
SQUAMOUS cell carcinoma , *BLADDER , *CYSTECTOMY , *BLADDER cancer , *MULTIVARIABLE testing - Abstract
Purpose: To assess the effect of event-free survival duration on cancer-specific mortality (CSM) after radical cystectomy (RC) in nonmetastatic muscle-invasive squamous cell carcinoma of the urinary bladder.Methods: RC patients treated for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder were identified within the Surveillance, Epidemiology, and End Results database (2000-2018). Independent predictor status for CSM of T and N stage groupings (i.e., T2N0, T3N0, T4N0, and TanyN1-3) was tested in multivariable Cox-regression models. Conditional 5-year CSM-free estimates were assessed at baseline and at 4 specific event-free survival times (i.e. 6, 12, 18 and 24 months), within each of the 4 examined stage groups.Results: Of 981 RC patients, 206 (21%), 416 (42%), 152 (16%), and 207 (21%) were T2N0, T3N0, T4N0, and TanyN1-3, respectively. In multivariable Cox-regression models T3N0 (HR 1.94), T4N0 (HR 5.22), and TanyN1-3 (HR 6.62) were independent predictors of CSM, relative to T2N0. In conditional survival analyses based on 24 months event-free status, survival estimates were: 89% for T2N0 vs. 76% at baseline (Δ = 13%), 84% for T3N0 vs. 58% at baseline (Δ = 26%), 69% for T4N0 vs. 25% at baseline (Δ = 44%), 69% for TanyN1-3 vs. 22% at baseline (Δ = 47%).Conclusions: Event-free status at 24 months of follow-up is associated with substantially higher CSM-free survival than when CSM-free survival is predicted at baseline. The magnitude of this effect is most pronounced in TanyN1-3 and T4N0 patients, intermediate in T3N0 and more modest, nonetheless important, in T2N0. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
23. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
- Author
-
Krajewski, Wojciech, Aumatell, Júlia, Subiela, José Daniel, Nowak, Łukasz, Tukiendorf, Andrzej, Moschini, Marco, Basile, Giuseppe, Poletajew, Sławomir, Małkiewicz, Bartosz, Del Giudice, Francesco, Maggi, Martina, Chung, Benjamin I., Cimadamore, Alessia, Galosi, Andrea Benedetto, Fave, Rocco Francesco Delle, D'Andrea, David, Shariat, Shahrokh F, Hornak, Jakub, Babjuk, Marko, and Chorbińska, Joanna
- Subjects
- *
BLADDER cancer , *DISEASE risk factors , *TRANSITIONAL cell carcinoma , *UROTHELIUM , *PROGRESSION-free survival , *CANCER invasiveness , *TUMOR grading , *DISEASE progression , *CANCER relapse , *RETROSPECTIVE studies , *NON-muscle invasive bladder cancer , *RISK assessment , *BCG vaccines - Abstract
Purpose: Non-muscle-invasive bladder cancers (NMIBC) constitute 3-quarters of all primary diagnosed bladder tumors. For risk-adapted management of patients with NMIBC, different risk group systems and predictive models have been developed. This study aimed to externally validate EORTC2016, CUETO and novel EAU2021 risk scoring models in a multi-institutional retrospective cohort of patients with high-grade NMIBC who were treated with an adequate BCG immunotherapy.Methods: The Kaplan-Meier estimates for recurrence-free survival and progression-free survival were performed, predictive abilities were assessed using the concordance index (C-index) and area under the curve (AUC).Results: A total of 1690 patients were included and the median follow-up was 51 months. For the overall cohort, the estimates recurrence-free survival and progression-free survival rates at 5-years were 57.1% and 82.3%, respectively. The CUETO scoring model had poor discrimination for disease recurrence (C-index/AUC for G2 and G3 grade tumors: 0.570/0.493 and 0.559/0.492) and both CUETO (C-index/AUC for G2 and G3 grade tumors: 0.634/0.521 and 0.622/0.525) EAU2021 (c-index/AUC: 0.644/0.522) had poor discrimination for disease progression.Conclusion: Both the CUETO and EAU2021 scoring systems were able to successfully stratify risks in our population, but presented poor discriminative value in predicting clinical events. Due to the lack of data, model validation was not possible for EORTC2016. The CUETO and EAU2021 systems overestimated the risk, especially in highest-risk patients. The risk of progression according to EORTC2016 was slightly lower when compared with our population analysis. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
24. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy.
- Author
-
Grossmann, Nico C., Schuettfort, Victor M., Pradere, Benjamin, Rajwa, Pawel, Quhal, Fahad, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Motlagh, Reza S., Aydh, Abdulmajeed, Katayama, Satoshi, Moschini, Marco, Fankhauser, Christian D., Hermanns, Thomas, Abufaraj, Mohammad, Mun, Dong-Ho, Zimmermann, Kristin, Fajkovic, Harun, Haydter, Martin, and Shariat, Shahrokh F.
- Subjects
- *
BLADDER cancer , *CANCER prognosis , *CYSTECTOMY , *RECEIVER operating characteristic curves , *DECISION making , *OVERALL survival , *BLADDER , *INFLAMMATION , *RETROSPECTIVE studies , *PROGNOSIS , *TRANSITIONAL cell carcinoma ,BLADDER tumors - Abstract
Purpose: To investigate the predictive and prognostic value of the preoperative systemic immune-inflammation index (SII) in patients undergoing radical cystectomy (RC) for clinically non-metastatic urothelial cancer of the bladder (UCB).Methods: Overall, 4,335 patients were included, and the cohort was stratified in two groups according to SII using an optimal cut-off determined by the Youden index. Uni- and multivariable logistic and Cox regression analyses were performed, and the discriminatory ability by adding SII to a reference model based on available clinicopathologic variables was assessed by area under receiver operating characteristics curves (AUC) and concordance-indices. The additional clinical net-benefit was assessed using decision curve analysis (DCA).Results: High SII was observed in 1879 (43%) patients. On multivariable preoperative logistic regression, high SII was associated with lymph node involvement (LNI; P = 0.004), pT3/4 disease (P <0.001), and non-organ confined disease (NOCD; P <0.001) with improvement of AUCs for predicting LNI (P = 0.01) and pT3/4 disease (P = 0.01). On multivariable Cox regression including preoperative available clinicopathologic values, high SII was associated with recurrence-free survival (P = 0.028), cancer-specific survival (P = 0.005), and overall survival (P = 0.006), without improvement of concordance-indices. On DCAs, the inclusion of SII did not meaningfully improve the net-benefit for clinical decision-making in all models.Conclusion: High preoperative SII is independently associated with pathologic features of aggressive disease and worse survival outcomes. However, it did not improve the discriminatory margin of a prediction model beyond established clinicopathologic features and failed to add clinical benefit for decision making. The implementation of SII as a part of a panel of biomarkers in future studies might improve decision-making. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
25. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy
- Author
-
Wei Shen Tan, Badrianath Konety, Stephen A. Boorjian, Anthony Koupparis, David D'Andrea, Matt Perry, Stefania Zamboni, Gabriele Tuderti, Giuseppe Simone, Wassim Kassouf, Alberto Briganti, Michael Rink, Shahrokh F. Shariat, Pierre I. Karakiewicz, Evanguelos Xylinas, Douglas S. Scherr, Francesco Montorsi, Agostino Mattei, Anoop Meraney, Prasanna Sooriakumaran, Francesco Soria, Atiqullah Aziz, Edward Rowe, Philipp Baumeister, Suprita Krishna, Marco Moschini, John D. Kelly, Guillaume Ploussard, Morgan Rouprêt, Romain Mathieu, Michele Galucci, Moschini, Marco, Soria, Francesco, Mathieu, Romain, Xylinas, Evanguelo, D'Andrea, David, Tan, Wei Shen, Kelly, John D., Simone, Giuseppe, Tuderti, Gabriele, Meraney, Anoop, Krishna, Suprita, Konety, Badrianath, Zamboni, Stefania, Baumeister, Philipp, Mattei, Agostino, Briganti, Alberto, Montorsi, Francesco, Galucci, Michele, Rink, Michael, Karakiewicz, Pierre I., Rouprêt, Morgan, Aziz, Atiqullah, Perry, Matt, Rowe, Edward, Koupparis, Anthony, Kassouf, Wassim, Scherr, Douglas S., Ploussard, Guillaume, Boorjian, Stephen A., Sooriakumaran, Prasanna, and Shariat, Shahrokh F.
- Subjects
Male ,Propensity score ,Robotic assisted ,medicine.medical_treatment ,030232 urology & nephrology ,Robotic-assisted ,Logistic regression ,0302 clinical medicine ,Postoperative Complications ,Robotic Surgical Procedures ,Soft tissue surgical margin ,Adjuvant ,Bladder cancer ,Soft tissue ,Margins of Excision ,Middle Aged ,Treatment Outcome ,Oncology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Cohort ,Open ,Radical cystectomy ,Soft tissue surgical margins ,Aged ,Carcinoma, Transitional Cell ,Cystectomy ,Female ,Follow-Up Studies ,Humans ,Length of Stay ,Lymph Node Excision ,Propensity Score ,Retrospective Studies ,Urinary Bladder ,Urinary Bladder Neoplasms ,medicine.medical_specialty ,Urology ,03 medical and health sciences ,medicine ,Chemotherapy ,business.industry ,Carcinoma ,medicine.disease ,Surgery ,Propensity score matching ,Transitional Cell ,business ,Surgical Margins Status - Abstract
Introduction The use of robotic-assisted radical cystectomy (RARC) is becoming more widespread. While its safety is accepted, its oncological efficacy as compared to the current standard, open radical cystectomy (ORC), remains debatable. Materials and methods The aim of this study is to compare the rates of positive soft tissue surgical margins (STSM), between patients treated with RARC or ORC, using a large contemporaneous collaborative database. We included 2,536 patients with urothelial carcinoma of the bladder treated at 26 institutions. A propensity-score matching 1:1 was performed with 3 ORC patients matched to 1 RARC patient. The final cohort included 1,614 patients. Uni- and multivariable logistic regression analyses tested the impact of surgical technique on STSM status, before and after propensity-score matching. Results Overall, 870 (34%) patients underwent RARC and 1,666 (66%) ORC. The overall STSM rate was 11%; 10% in the ORC group and 13% in the RARC group. Within the propensity-score-matched cohort, the positive STSM rate were 14% and 13% in the ORC and RARC group, respectively (P = 0.1). In multivariable analysis, after propensity match RARC approach was not associated with the risk of a positive STSM (P = 0.1). These results were confirmed in the subgroup of patients with pathologic non–organ-confined or organ-confined diseases. Conclusions While treatment with RARC is associated with a higher absolute rate of STSM, the difference did not remain after adjustment for the effects of other established prognostic factors. Results from ongoing trials are awaited to assess the validity of these findings.
- Published
- 2018
26. Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder.
- Author
-
Schuettfort, Victor M., D'Andrea, David, Quhal, Fahad, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Sari Motlagh, Reza, Rink, Michael, Abufaraj, Mohammad, Karakiewicz, Pierre I., Luzzago, Stefano, Rouprêt, Morgan, Chlosta, Piotr, Babjuk, Marko, Deuker, Marina, Moschini, Marco, Shariat, Shahrokh F., and Pradere, Benjamin
- Subjects
- *
TRANSITIONAL cell carcinoma , *RECEIVER operating characteristic curves , *PROGNOSTIC models , *LOGISTIC regression analysis , *CYSTECTOMY , *IMMUNOTHERAPY , *ILEAL conduit surgery , *BLOOD proteins , *PREOPERATIVE period , *SERUM albumin , *TREATMENT effectiveness , *GLOBULINS ,BLADDER tumors - Abstract
Introduction: The Albumin-Globulin Ratio (AGR; albumin/total protein - albumin) has been associated with oncological outcome in various malignancies. However, its role in urothelial carcinoma of the bladder (UCB) has not been clearly established. In this study, we assessed the association of preoperative AGR (pAGR) with survival in patients who underwent radical cystectomy (RC) for UCB.Material and Methods: We conducted a retrospective analysis of an established multicenter database of 4.335 patients who were treated with RC for UCB. The cohort was divided into 2 groups according to the pAGR status. Binominal logistic regression as well as uni- and multivariable Cox regression analyses were used. The predictive value of the models was assessed by calculating receiver operating characteristics curves and concordance-indices (C-Index). The additional clinical value was assessed using the decision curve analysis (DCA).Results: Overall, 1.670 patients (38.5%) had a low pAGR. On multivariable logistic regression analyses, low pAGR was associated with an increased risk of ≥pT3 disease at RC (odds ratio [OR] 1.15, 95% confidence interval [CI] 1.01-1.31, P= 0.04). On multivariable Cox regression analyses, low pAGR remained associated with worse recurrence-free survival (RFS, HR 1.24, 95% CI 1.1-1.37, P< 0.001), cancer-specific survival (CSS, HR 1.23, 95% CI 1.1-1.38, P< 0.001) and overall survival (OS, HR 1.17, 95% CI 1.07-1.28, P< 0.001). The addition of pAGR to multiple prognostic models that were respectively fitted for clinical and postoperative variables did not improve the predictive accuracy.Conclusion: pAGR status is an independent predictor of ≥pT3 disease, therefore it could help identify patients who have a higher likelihood to benefit from neoadjuvant systemic therapy. While pAGR was independently associated with RFS, CSS, and OS, it did not improve the predictive accuracy and clinical value beyond obtained by information already available. The predictive value of this biomarker in the age of immunotherapy needs further evaluation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
27. Primary Ta high grade bladder tumors: Determination of the risk of progression.
- Author
-
Quhal, Fahad, D'Andrea, David, Soria, Francesco, Moschini, Marco, Abufaraj, Mohammad, Rouprêt, Morgan, Karakiewicz, Pierre I., Yang, Lin, Mostafaei, Hadi, Laukhtina, Ekaterina, Mori, Keiichiro, Sari Motlagh, Reza, Rink, Michael, and Shariat, Shahrokh F.
- Subjects
- *
TUMOR grading , *DIAGNOSIS , *DISEASE relapse , *REGRESSION analysis , *DISEASE progression , *BLADDER cancer , *RETROSPECTIVE studies , *RISK assessment ,BLADDER tumors - Abstract
Purpose: TaG3 bladder cancer is an under-investigated disease and because of its rarity it is commonly studies together with T1G3 disease. We sought to exclusively study TaG3 disease and to determine the factors associated with disease progression.Material and Method: We retrospectively studied patients with primary TaG3 bladder cancer. Progression to ≥pT1 and pT2 were analyzed using Cox and competing-risk regression analyses.Results: Of 3,505 consecutive patients with nonmuscle invasive bladder cancer, 285 patients had primary TaG3 without concomitant carcinoma in-situ. Progression to ≥pT1 occurred in 21 patients (7.4%). In a multivariable competing-risk regression analysis, intravesical Bacillus Calmette-Guerin (BCG) was significantly associated with a lower risk of progression to ≥pT1 (HR 0.23, 95%CI 0.08-0.64, P = 0.005). Recurrence in the first year of diagnosis was significantly associated with an increased risk of stage progression to ≥pT1 (HR 7.81, 95%CI 2.50-24.44, P < 0.001). Progression to ≥T2 was observed in 9 patients (3.2%). In univariable competing-risk regression analyses, intravesical BCG was significantly associated with a lower risk of progression to ≥pT2 (HR 0.11, 95%CI 0.04-0.47, P = 0.003). On the other hand, recurrence in the first year of diagnosis was significantly associated with an increased risk of stage progression to ≥T2 (HR 7.12, 95%CI 1.50-33.77, P = 0.013). In a subgroup of 199 patients who were treated with BCG, there was no statistically significant association between tumor recurrence in the 1st year of diagnosis and stage progression to ≥pT1 (P = 0.14) or ≥pT2(P = 0.19).Conclusion: Patients with TaG3 bladder cancer are considered high risk but if appropriately treated with BCG that risk is considerably mitigated. Our data support that TaG3 without concomitant carcinoma in-situ should not be considered as aggressive as T1G3 as it has a lower risk of progression to muscle-invasive bladder cancer. Recurrence in the first year after diagnosis is the strongest predictor of progression to muscle-invasive bladder cancer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
28. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer
- Author
-
Paolo Dell'Oglio, Umberto Capitanio, Marco Moschini, Zhe Tian, Giorgio Gandaglia, Fred Saad, Vincent Trudeau, Sami-Ramzi Leyh-Bannurah, Alberto Briganti, Francesco Montorsi, Markus Graefen, Marco Bandini, Pierre I. Karakiewicz, Nicola Fossati, Alessandro Larcher, Dell'Oglio, Paolo, Bandini, Marco, Leyh-Bannurah, Sami-Ramzi, Tian, Zhe, Trudeau, Vincent, Larcher, Alessandro, Fossati, Nicola, Moschini, Marco, Gandaglia, Giorgio, Capitanio, Umberto, Briganti, Alberto, Graefen, Marku, Montorsi, Francesco, Saad, Fred, and Karakiewicz, Pierre I
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Survival ,Cost ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Adenocarcinoma ,law.invention ,Androgen deprivation therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Randomized controlled trial ,law ,Risk Factors ,Internal medicine ,medicine ,Surveillance, Epidemiology, and End Results ,Humans ,High metastatic risk ,External beam radiotherapy ,RT with ADT ,Aged, 80 and over ,business.industry ,Confounding ,Prostatic Neoplasms ,Androgen Antagonists ,Radiotherapy Dosage ,Chemoradiotherapy ,medicine.disease ,Prognosis ,Comorbidity ,Radiation therapy ,Survival Rate ,030220 oncology & carcinogenesis ,Female ,business ,Elderly patient ,Follow-Up Studies - Abstract
Objective Several randomized controlled trials have documented significant overall survival benefit in high metastatic risk prostate cancer (PCa) patients treated with combination of androgen deprivation therapy (ADT) at radiotherapy (RT) relative to RT alone. Unfortunately, elderly patients are either not included or are underrepresented in these trials. In consequence, the survival benefit of combination of ADT at RT in the elderly warrants detailed reassessment, including its cost. Methods Between 1991 and 2009 within the Surveillance Epidemiology and End Results (SEER)-Medicare-linked database, we identified 3,692 patients aged 80 years or more with clinical T1–T2 PCa and WHO histological grade 3, or clinical T3–T4 PCa and any histological grade, treated with or without combination of ADT at RT. Competing risks analyses focused on cancer-specific mortality (CSM) and other-cause mortality, after accounting for confounders. All analyses were repeated in patients with no comorbidity and in most contemporary patients, treated between 2001 and 2009. Finally, we assessed median annual cost according to use of combination of ADT at RT, after adjusting for patient and tumor characteristics. Results In competing-risks multivariable analyses, no statistically significant difference was observed in CSM and other-cause mortality between patients treated with or without combination of ADT at RT. Same results were recorded in subgroup analyses of patients with no comorbidity and in most contemporary patients. The median annual costs of $36,140 and of $47,510 were recorded, respectively in patients treated without and with ADT at RT. Conclusion Our findings failed to confirm that combination of ADT at RT reduces CSM rates in high metastatic risk PCa patients aged 80 years or more. Moreover, combination of ADT at RT resulted in a significant cost increase, relative to RT alone.
- Published
- 2017
29. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer
- Author
-
Marco Moschini, Christian Seitz, Mehmet Özsoy, Romain Mathieu, Martin Susani, Beat Foerster, Anna Czech, Shahrokh F. Shariat, David D'Andrea, Morgan Rouprêt, Mohammad Abufaraj, Pierre I. Karakiewicz, Alberto Briganti, Özsoy, Mehmet, D'Andrea, David, Moschini, Marco, Foerster, Beat, Abufaraj, Mohammad, Mathieu, Romain, Briganti, Alberto, Karakiewicz, Pierre I., Roupret, Morgan, Seitz, Christian, Czech, Anna Katarzyna, Susani, Martin, and Shariat, Shahrokh F.
- Subjects
Biochemical recurrence ,Male ,medicine.medical_specialty ,Lymphovascular invasion ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Disease-Free Survival ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Tertiary Gleason pattern ,Interquartile range ,medicine ,Humans ,Prospective Studies ,Gleason score ,Prospective cohort study ,Aged ,Retrospective Studies ,Prostatectomy ,business.industry ,breakpoint cluster region ,Prostate ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Radical prostatectomy ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Lymph Node Excision ,Kallikreins ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Aim To assess the predictive value of TGP on biochemical recurrence (BCR) and its association with clinicopathological outcomes in a large, multicenter cohort of patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP). Materials and methods Records of 6,041 patients who were treated with RP between 2000 and 2011 for clinically nonmetastatic PCa were, retrospectively, analyzed from prospectively collected datasets. BCR-free survival rates were assessed using univariable and multivariable cox-regression analyses. Results Median patient age was 61 years (interquartile range [IQR]: 57–66) with a median preoperative prostrate specific antigen of 6 ng/ml (IQR: 4–9). Overall, 28% of patients had Gleason score (GS) 6, 0.3% GS 6 + TGP, 33% GS 7 (3 + 4), 0.2% GS 7 (3 + 4) + TGP, 22% GS 7 (4 + 3), 0.2% GS 7 (4 + 3) + TGP, 0.1% GS 8 and 0.4% GS 9 or 10. Median follow-up was 45 months (IQR: 31–57). Harboring a TGP was associated with higher rates of positive surgical margins, lymphovascular invasion, extraprostatic extension, and seminal vesicle invasion than their counterparts within the same GS group as well as in the next higher GS group (all P ≤ 0.05). At 5 years post-RP, BCR estimates were 5% for patients with GS 6, 13% for patients with GS 6 + TGP, 6% for patients with GS 7 (3 + 4), 22% for patients with GS 7 (3 + 4) + TGP, 16% for patients with GS 7 (4 + 3), 41% for patients with GS 7 (4 + 3) + TGP, 38% for patients with GS 8 (4 + 4) and 46% for patients with GS 9 or 10. Patients harboring a TGP had higher BCR rates than the patients in the next higher GS group: GS 6 + TGP vs. GS 7 (3 + 4), HR = 1.6, P = 0.02 and GS 7 (3 + 4)+TGP vs. GS 7 (4 + 3), HR = 1.4, P = 0.03. Patients with a TGP in the GS 7 (4 + 3) group had comparable BCR rates as patients with GS = 8 ( P = 0.4) and GS 9 to 10 ( P = 0.2). On multivariable analysis that adjusted for the effects of preoperative prostrate specific antigen, nodal involvement, positive surgical margin, extraprostatic disease (pT3a), seminal vesicle invasion (pT3b) and different institution, harboring a TGP showed higher risk of developing BCR within the same GS group and comparable risk of developing BCR with the next higher GS group. Conclusion Patients with TGP at RP have adverse clinicopathological features when compared to their counterparts in the same and the next higher GS group without TGP. Risk of developing BCR increases with the presence of TGP within the same GS group. This risk seems to be comparable between patients with TGP and their counterparts in the next higher GS group without TGP. Knowledge of TGP in RP specimens is likely to improve risk stratification, patient counseling and follow-up scheduling. Further prospective studies that control significant clinical endpoints such as metastasis and mortality are necessary for more significant predictions.
- Published
- 2017
30. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer
- Author
-
Renzo Colombo, Francesco Montorsi, Alberto Briganti, Emilio Arbelaez, Emanuele Zaffuto, Shahrokh F. Shariat, Paolo Dell‘Oglio, Julian Cornelius, Agostino Mattei, Andrea Salonia, Marco Moschini, Andrea Gallina, Moschini, Marco, Arbelaez, Emilio, Cornelius, Julian, Mattei, Agostino, Shariat, Shahrokh F., Dell′Oglio, Paolo, Zaffuto, Emanuele, Salonia, Andrea, Montorsi, Francesco, Briganti, Alberto, Colombo, Renzo, and Gallina, Andrea
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,ePLND ,PLND ,Cystectomy ,Inferior mesenteric artery ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,medicine.artery ,medicine ,Humans ,Pelvic Neoplasms ,Neoplasm Invasiveness ,Prospective Studies ,Lymph node ,Aged ,Retrospective Studies ,Bladder cancer ,business.industry ,Middle Aged ,medicine.disease ,Prognosis ,Radical cystectomy ,Dissection ,medicine.anatomical_structure ,Oncology ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Concomitant ,Lymphatic Metastasis ,Node metastase ,Female ,Radiology ,Lymph Nodes ,business ,Follow-Up Studies - Abstract
Background: Pelvic lymph node dissection (PLND) has a diagnostic and therapeutic role during radical cystectomy in bladder cancer patients. However, at the time, no prospective data supports the value of extended PLND in improving survival expectances. We sought to describe incidence and location of node metastases in patients treated with extended and superextended PLND. Methods: We evaluated 653 contemporary patients with clinically nonmetastatic high risk nonmuscle invasive or muscle-invasive bladder cancer treated with radical cystectomy and extended or superextended PLND without neoadjuvant chemotherapy at a single tertiary referral center between 1990 and 2013. Limited PLND is defined as the removal of obturator and internal iliac nodes. Standard included also the external iliac nodes. Extended includes also common and presacral nodes. Finally, superextended PLND includes all the nodes removed along the inferior mesenteric artery. We evaluated incidence of pathologically node metastases. Logistic regression analyses evaluate preoperative and pathologic characteristics to the risk of harboring node metastases in the extended and superextended template. Results: Overall, 191 (29.3%) patients were found with pathologically node confirmed metastases. Of these, 56 (29.3%) patients were found with a single node metastasis, while 135 (70.7%) had multiple node metastases. The vast majority of patients were found with node metastases standard template (n = 172, 26.3%), on the other hand 30 (4.6%) and 21 (3.2%) patients had node metastases in extended and superextended templates, respectively. However, of these only 2 patients were found without concomitant lymph node metastases in the limited or standard templates. On multivariable analyses, cN+ status (odds ratio = 4.40, P
- Published
- 2016
31. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration.
- Author
-
Soria, Francesco, Giordano, Andrea, D'Andrea, David, Moschini, Marco, Rouprêt, Morgan, Margulis, Vitaly, Karakiewicz, Pierre I., Briganti, Alberto, Bensalah, Karim, Mathieu, Romain, Chlosta, Piotr, Babjuk, Marek, Glybochko, Petr V., Enikeev, Dmitry V., Remzi, Mesut, Gust, Kilian, Gontero, Paolo, and Shariat, Shahrokh F.
- Subjects
- *
TRANSITIONAL cell carcinoma , *GLASGOW Coma Scale , *LOGISTIC regression analysis , *FORECASTING , *RESEARCH , *INFLAMMATION , *RESEARCH methodology , *PROGNOSIS , *RETROSPECTIVE studies , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *KIDNEY tumors , *DISEASE complications ,URETER tumors - Abstract
Introduction and Objectives: To evaluate the prognostic role of modified Glasgow prognostic score (mGPS) for the prediction of oncological outcomes in a retrospective large multicenter cohort of upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy (RNU).Materials and Methods: We retrospectively analyzed a multicenter cohort of patients treated with RNU for clinically nonmetastatic UTUC. Multivariable logistic regression analyses were performed to evaluate the ability of mGPS to predict nonorgan confined (NOC) disease and lymph-node involvement (LNI) at RNU. Multivariable Cox-regression models were performed to evaluate the preoperative and postoperative prognostic effect of mGPS on survival outcomes.Results: Overall, 2,492 patients were included in the study. Of these, 1,929 (77%), 530 (21%), and 33 (1%) had a mGPS of 0, 1, and 2, respectively. mGPS was associated with characteristics of tumor aggressiveness and independently predicted LNI and NOC at RNU (both P < 0.05). On univariable and multivariable Cox-regression analyses, higher mGPS was independently associated with recurrence-free, cancer-specific, and overall survival, both in a preoperative and in a postoperative setting. The inclusion of mGPS significantly improved the discrimination of a preoperative model for the prediction of oncologic outcomes compared to standard prognosticators.Conclusions: We found that mGPS is independently associated with clinicopathologic features and survival outcomes after RNU. Future studies should investigate the role of mGPS in a panel of preoperative markers for the prediction of NOC and LNI in UTUC patients, thus possibly improving the selection for perioperative systemic therapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
32. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups
- Author
-
Nicolò Buffi, Shahrokh F. Shariat, Alberto Briganti, Massimo Freschi, Francesco Montorsi, Franco Gaboardi, Giorgio Guazzoni, Paolo Dell‘Oglio, Nazareno Suardi, Pierre I. Karakiewicz, Nicola Fossati, Roberta Lucianò, Giorgio Gandaglia, Andrea Gallina, Marco Moschini, Giovanni Lughezzani, Suardi, Nazareno, Dell'Oglio, Paolo, Gallina, Andrea, Gandaglia, Giorgio, Buffi, Nicolo, Moschini, Marco, Fossati, Nicola, Lughezzani, Giovanni, Karakiewicz Pierre, I., Freschi, Massimo, Luciano, Roberta, Shariat Shahrokh, F., Guazzoni, Giorgio, Gaboardi, Franco, Montorsi, Francesco, and Briganti, Alberto
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,030232 urology & nephrology ,Positive surgical margin ,Logistic regression ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,medicine ,Robot-assisted radical prostatectomy ,Humans ,In patient ,Pathological ,Prostatectomy ,business.industry ,Risk Factor ,Confounding ,Prostatic Neoplasms ,Robotics ,medicine.disease ,Surgery ,Robotic ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Prostatic Neoplasm ,Positive Surgical Margin ,business ,Human - Abstract
Objectives Recent studies showed that robot-assisted radical prostatectomy (RARP) represents an oncologically safe procedure in patients with prostate cancer (PCa), where the rate of positive surgical margins (PSMs) might be lower in patients treated with RARP as compared with that of those undergoing the open approach (open RP [ORP]). The aim of this study is to analyze the rate of PSMs according to preoperative risk groups in a large cohort of patients treated with RARP and ORP in a single institution with standardized surgical technique and pathological examination. Materials and methods We evaluated 6,194 consecutive patients with PCa undergoing either ORP (71.1%) or RARP (28.9%) between 1992 and 2014. Logistic regression analyses were used to test the association between type of surgery and PSMs in each preoperative risk group (low vs. intermediate vs. high) after adjusting for confounders. Results Overall, 21.6% patients had PSMs. RARP was associated with a lower rate of PSMs in low-risk (11.5 vs. 15.4%, P = 0.01), intermediate-risk (18.9 vs. 23.5%, P = 0.008), and high-risk patients (19.7 vs. 30.1%, P
- Published
- 2015
33. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
- Author
-
Dell’Oglio, Paolo, Bandini, Marco, Leyh-Bannurah, Sami-Ramzi, Tian, Zhe, Trudeau, Vincent, Larcher, Alessandro, Fossati, Nicola, Moschini, Marco, Gandaglia, Giorgio, Capitanio, Umberto, Briganti, Alberto, Graefen, Markus, Montorsi, Francesco, Saad, Fred, Karakiewicz, Pierre I., and Dell'Oglio, Paolo
- Subjects
- *
PROSTATE cancer treatment , *HEALTH outcome assessment , *DISEASE progression , *ANDROGENS , *OLDER patients , *CANCER treatment , *PROSTATE tumors treatment , *ADENOCARCINOMA , *ANTIANDROGENS , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PROSTATE tumors , *RADIATION doses , *RESEARCH , *SURVIVAL , *EVALUATION research , *ECONOMICS , *THERAPEUTICS ,RISK of metastasis - Abstract
Objective: Several randomized controlled trials have documented significant overall survival benefit in high metastatic risk prostate cancer (PCa) patients treated with combination of androgen deprivation therapy (ADT) at radiotherapy (RT) relative to RT alone. Unfortunately, elderly patients are either not included or are underrepresented in these trials. In consequence, the survival benefit of combination of ADT at RT in the elderly warrants detailed reassessment, including its cost.Methods: Between 1991 and 2009 within the Surveillance Epidemiology and End Results (SEER)-Medicare-linked database, we identified 3,692 patients aged 80 years or more with clinical T1-T2 PCa and WHO histological grade 3, or clinical T3-T4 PCa and any histological grade, treated with or without combination of ADT at RT. Competing risks analyses focused on cancer-specific mortality (CSM) and other-cause mortality, after accounting for confounders. All analyses were repeated in patients with no comorbidity and in most contemporary patients, treated between 2001 and 2009. Finally, we assessed median annual cost according to use of combination of ADT at RT, after adjusting for patient and tumor characteristics.Results: In competing-risks multivariable analyses, no statistically significant difference was observed in CSM and other-cause mortality between patients treated with or without combination of ADT at RT. Same results were recorded in subgroup analyses of patients with no comorbidity and in most contemporary patients. The median annual costs of $36,140 and of $47,510 were recorded, respectively in patients treated without and with ADT at RT.Conclusion: Our findings failed to confirm that combination of ADT at RT reduces CSM rates in high metastatic risk PCa patients aged 80 years or more. Moreover, combination of ADT at RT resulted in a significant cost increase, relative to RT alone. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
34. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
- Author
-
D'Andrea, David, Özsoy, Mehmet, Seitz, Christian, Shariat, Shahrokh F., Moschini, Marco, Foerster, Beat, Abufaraj, Mohammad, Mathieu, Romain, Susani, Martin, Briganti, Alberto, Karakiewicz, Pierre I., Roupret, Morgan, and Czech, Anna Katarzyna
- Subjects
- *
PROSTATECTOMY , *GLEASON grading system , *PROSTATE cancer , *CANCER relapse , *SURGICAL site , *BLOOD coagulation factors , *COMPARATIVE studies , *SURGICAL excision , *LONGITUDINAL method , *LYMPH node surgery , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *PROSTATE , *PROSTATE tumors , *RESEARCH , *PROSTATE-specific antigen , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *TUMOR grading - Abstract
Aim: To assess the predictive value of TGP on biochemical recurrence (BCR) and its association with clinicopathological outcomes in a large, multicenter cohort of patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP).Materials and Methods: Records of 6,041 patients who were treated with RP between 2000 and 2011 for clinically nonmetastatic PCa were, retrospectively, analyzed from prospectively collected datasets. BCR-free survival rates were assessed using univariable and multivariable cox-regression analyses.Results: Median patient age was 61 years (interquartile range [IQR]: 57-66) with a median preoperative prostrate specific antigen of 6ng/ml (IQR: 4-9). Overall, 28% of patients had Gleason score (GS) 6, 0.3% GS 6 + TGP, 33% GS 7 (3 + 4), 0.2% GS 7 (3 + 4) + TGP, 22% GS 7 (4 + 3), 0.2% GS 7 (4 + 3) + TGP, 0.1% GS 8 and 0.4% GS 9 or 10. Median follow-up was 45 months (IQR: 31-57). Harboring a TGP was associated with higher rates of positive surgical margins, lymphovascular invasion, extraprostatic extension, and seminal vesicle invasion than their counterparts within the same GS group as well as in the next higher GS group (all P ≤ 0.05). At 5 years post-RP, BCR estimates were 5% for patients with GS 6, 13% for patients with GS 6 + TGP, 6% for patients with GS 7 (3 + 4), 22% for patients with GS 7 (3 + 4) + TGP, 16% for patients with GS 7 (4 + 3), 41% for patients with GS 7 (4 + 3) + TGP, 38% for patients with GS 8 (4 + 4) and 46% for patients with GS 9 or 10. Patients harboring a TGP had higher BCR rates than the patients in the next higher GS group: GS 6 + TGP vs. GS 7 (3 + 4), HR = 1.6, P = 0.02 and GS 7 (3 + 4)+TGP vs. GS 7 (4 + 3), HR = 1.4, P = 0.03. Patients with a TGP in the GS 7 (4 + 3) group had comparable BCR rates as patients with GS = 8 (P = 0.4) and GS 9 to 10 (P = 0.2). On multivariable analysis that adjusted for the effects of preoperative prostrate specific antigen, nodal involvement, positive surgical margin, extraprostatic disease (pT3a), seminal vesicle invasion (pT3b) and different institution, harboring a TGP showed higher risk of developing BCR within the same GS group and comparable risk of developing BCR with the next higher GS group.Conclusion: Patients with TGP at RP have adverse clinicopathological features when compared to their counterparts in the same and the next higher GS group without TGP. Risk of developing BCR increases with the presence of TGP within the same GS group. This risk seems to be comparable between patients with TGP and their counterparts in the next higher GS group without TGP. Knowledge of TGP in RP specimens is likely to improve risk stratification, patient counseling and follow-up scheduling. Further prospective studies that control significant clinical endpoints such as metastasis and mortality are necessary for more significant predictions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
35. Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis.
- Author
-
Zaffuto, Emanuele, Pompe, Raisa, Bondarenko, Helen Davis, Moschini, Marco, Dell’Oglio, Paolo, Gandaglia, Giorgio, Fossati, Nicola, Shariat, Shahrokh F., Montorsi, Francesco, Briganti, Alberto, Karakiewicz, Pierre I., and Dell'Oglio, Paolo
- Subjects
- *
CYSTECTOMY , *HOSPITAL care , *SURGICAL complications , *ONCOLOGY , *HOSPITAL beds - Abstract
Introduction: The length of stay prior to surgery increases the risk of postoperative infections (PIs) in several surgical settings, such as cardiac, orthopedic, and general surgery. However, data for urological oncology procedures are limited. We examined PI rates after radical cystectomy (RC) according to the length of stay prior to RC (LOSPRC).Materials and Methods: A total of 24,242 patients with bladder cancer treated with RC between 1998 and 2013 were abstracted from the National Inpatients Sample database. We evaluated changes over time in LOSPRC (0 vs. 1 vs. 2 days or more) and tested its effect on PI rates. Multivariable logistic regression analyses were adjusted for the year of surgery, sex, age, ethnicity, comorbidities, hospital location, teaching status, hospital surgical volume, and number of hospital beds.Results: Overall, 19,401 (80.0%), 3,990 (16.5%), and 851 (3.5%) individuals with LOSPRC of 0, 1. and 2 or more were identified. The proportion of LOSPRC 0 patients increased from 61.4% in 1998 to 91.0% in 2013 (P<0.001), whereas the opposite trend was observed for LOSPRC 1 and 2 or more. In multivariable logistic regression analyses predicting PIs, LOSPRC of 1 (odds ratio: 1.38; 95% CI: 1.25-1.53; P<0.001) and LOSPRC of 2 or more (odds ratio: 2.15; 95% CI: 1.81-2.55; P<0.001) achieved independent predictor status.Conclusions: A delay in surgery as short as 1 day significantly increases the risk of PIs after RC. In consequence, same day of admission surgery policies should be further promoted to reduce the risk of PIs. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
36. Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping.
- Author
-
Gandaglia, Giorgio, Karnes, R. Jeffrey, Sivaraman, Arjun, Moschini, Marco, Fossati, Nicola, Zaffuto, Emanuele, Dellʼoglio, Paolo, Cathelineau, Xavier, Montorsi, Francesco, Sanchez-Salas, Rafael, and Briganti, Alberto
- Subjects
- *
PROSTATE cancer patients , *PROSTATECTOMY , *REGRESSION analysis , *SURGICAL complications , *PATHOLOGY - Abstract
Background: According to the novel prostate cancer (PCa) grade grouping, men with Gleason score 8 should be included in the grade group 4 regardless of primary and secondary scores. We aimed at evaluating the effect of Gleason patterns on the risk of recurrence in men with grade group 4 PCa.Patients and Methods: Overall, 1,089 patients treated with radical prostatectomy with grade group 4 PCa at final pathology were identified. Biochemical recurrence (BCR) was defined as 2 consecutive prostate-specific antigen values≥0.2ng/ml and rising. Clinical recurrence (CR) was defined as positive imaging after BCR. Kaplan-Meier analyses assessed time to BCR and CR. Multivariable Cox regression analyses assessed the impact of Gleason patterns on the risk of BCR and CR.Results: Overall, 295 (27.1%), 651 (59.8%), and 143 (13.1%) patients had pathologic Gleason pattern 3+5, 4+4, and 5+3. Overall, 435 (39.9%) patients had positive margins and 439 (30.2%), 300 (27.5%), 350 (32.1%), and 216 (19.8%) had pT2, pT3a, pT3b/4, and pN1 disease. Median follow-up was 83 months. Overall, 536 and 221 patients experienced BCR and CR. The 10-year BCR- and CR-free survival rates were 42.9% and 67.5% vs. 38.3% and 59.7% vs. 40.6% and 50.4% for patients with pathologic Gleason pattern 3+5 vs. 4+4 vs. 5+3, respectively (all P≤0.005). In multivariable analyses, patients with Gleason pattern 3+5 were at lower risk of BCR compared to those with 4+4 (P = 0.002). Men with Gleason pattern 3+5 were at lower risk of CR compared to those with 4+4 and 5+3 (all P≤ 0.01).Conclusions: Patients with a primary Gleason score 3 are at reduced risk of recurrence as compared to their counterparts with 4 or 5. Primary and secondary Gleason scores should be considered to stratify the risk of recurrence after surgery in patients with grade group 4 PCa. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.
- Author
-
Maj-Hes, Agnes B., Mathieu, Romain, Özsoy, Mehmet, Soria, Francesco, Moschini, Marco, Abufaraj, Mohammad, Briganti, Alberto, Roupret, Morgan, Karakiewicz, Pierre I., Klatte, Tobias, and Shariat, Shahrokh F.
- Subjects
- *
DISEASE relapse , *PROSTATE cancer , *PROSTATECTOMY , *OBESITY complications , *BODY mass index , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROSTATE tumors , *RESEARCH , *EVALUATION research ,RESEARCH evaluation - Abstract
Background: There are no clear data regarding the association between body mass index (BMI) and outcomes after radical prostatectomy (RP). This study aimed to investigate the association between BMI and biochemical recurrence (BCR) after RP in a large international contemporary cohort of patients with prostate cancer.Methods: We retrospectively analyzed data from 6,519 patients who underwent RP at 5 institutions. BMI was analyzed as both a continuous and categorical variable (<25kg/m2, 25-29.9kg/m2 [overweight], and≥30kg/m2 [obese]). The associations of continuous and categorical BMI with BCR were evaluated using univariable and multivariable Cox models, and prognostic accuracy was assessed using Harrell׳s C-index.Results: The median BMI was 28kg/m2 (interquartile range: 24-32kg/m2); 2,155 patients (33.1%) had a BMI = 25 to 29.9kg/m2 and 2,462 patients (37.7%) had a BMI≥30kg/m². Overweight and obese status were associated with extracapsular extension (P = 0.001) and seminal vesicle invasion (P = 0.005). The median follow-up was 28 months, and the estimated 5-year BCR-free survival rates for patients with a BMI<25kg/m2, 25 to 29.9kg/m2, and≥30kg/m² were 92%, 86%, and 79%, respectively (P<0.001). Multivariable analyses (adjusted for preoperative prostate-specific antigen levels, biopsy Gleason score, and clinical stage) revealed that obesity was associated with the risk of extracapsular extension (P<0.001), seminal vesicle invasion (P<0.001), and BCR (hazard ratio: 1.37, P<0.001). BMI and obesity remained associated with BCR after adjusting for postoperative characteristics. Addition of BMI slightly increased the discrimination of the multivariable clinical prognostic model (from 79.9%-80.9%).Conclusions: Overweight and obese status was associated with adverse pathological features and BCR after RP. However, the addition of BMI did not significantly improve the prognostic accuracy of a model that was based on established predictors. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
38. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely?
- Author
-
Fossati, Nicola, Rossi, Martina Sofia, Cucchiara, Vito, Gandaglia, Giorgio, Dell’Oglio, Paolo, Moschini, Marco, Suardi, Nazareno, Dehò, Federico, Montorsi, Francesco, Schiavina, Riccardo, Mottrie, Alexandre, Briganti, Alberto, and Dell'Oglio, Paolo
- Subjects
- *
PROSTATE cancer , *DIAGNOSIS , *PROSTATE cancer treatment , *PROSTATECTOMY , *CANCER relapse , *TREATMENT delay (Medicine) , *NONPARAMETRIC statistics , *LONGITUDINAL method , *MEDICAL care , *PATIENTS , *PROGNOSIS , *PROSTATE tumors , *SURVIVAL , *PREVENTION - Abstract
Objective: To test the prognostic role of treatment delay in patients affected by prostate cancer (PCa).Materials and Methods: The study included 2,653 patients treated with radical prostatectomy (RP) at a single institution between 2006 and 2011. The evaluated outcomes were biochemical recurrence (BCR) and clinical recurrence (CR). Multivariable Cox regression analysis was used to test the association between time from diagnosis to RP and oncological outcomes. Nonparametric curve fitting methods were used to graphically explore the relationship between time from diagnosis to RP and oncological outcomes. Sensitivity analyses were repeated in the subgroups of low-, intermediate-, and high-risk patients.Results: At median follow-up of 56 months (interquartile range: 26, 92), 283 patients experienced BCR, and 84 patients developed CR. Median time from PCa diagnosis to surgery was 2.8 months (interquartile range: 1.6, 4.7). At multivariable Cox regression analysis, time from biopsy to RP was significantly associated with an increased risk of BCR (hazard ratio = 1.02, P = 0.0005) and CR (hazard ratio = 1.03, P = 0.0002). Using Nonparametric curve fitting methods, a significant increased risk of BCR and CR after approximately 18 months was observed. However, when sensitivity analyses were repeated according to risk groups, this effect was maintained in high-risk patients only, and such time interval was reduced to 12 months.Conclusions: Despite the overall trend on higher rate of cancer relapse after RP, the effect of treatment delay from biopsy to RP was significantly evident in high-risk patients only. Even in high-risk patients surgical treatment can be postponed safely, but not beyond the 12-month landmark. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
39. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups.
- Author
-
Suardi, Nazareno, Dell׳Oglio, Paolo, Gallina, Andrea, Gandaglia, Giorgio, Buffi, Nicolò, Moschini, Marco, Fossati, Nicola, Lughezzani, Giovanni, Karakiewicz, Pierre I., Freschi, Massimo, Lucianò, Roberta, Shariat, Shahrokh F., Guazzoni, Giorgio, Gaboardi, Franco, Montorsi, Francesco, Briganti, Alberto, and Dell'Oglio, Paolo
- Subjects
- *
SURGICAL robots , *PROSTATECTOMY , *COMPARATIVE studies , *PREOPERATIVE care , *LOGISTIC regression analysis , *PROSTATE tumors , *ROBOTICS - Abstract
Objectives: Recent studies showed that robot-assisted radical prostatectomy (RARP) represents an oncologically safe procedure in patients with prostate cancer (PCa), where the rate of positive surgical margins (PSMs) might be lower in patients treated with RARP as compared with that of those undergoing the open approach (open RP [ORP]). The aim of this study is to analyze the rate of PSMs according to preoperative risk groups in a large cohort of patients treated with RARP and ORP in a single institution with standardized surgical technique and pathological examination.Materials and Methods: We evaluated 6,194 consecutive patients with PCa undergoing either ORP (71.1%) or RARP (28.9%) between 1992 and 2014. Logistic regression analyses were used to test the association between type of surgery and PSMs in each preoperative risk group (low vs. intermediate vs. high) after adjusting for confounders.Results: Overall, 21.6% patients had PSMs. RARP was associated with a lower rate of PSMs in low-risk (11.5 vs. 15.4%, P = 0.01), intermediate-risk (18.9 vs. 23.5%, P = 0.008), and high-risk patients (19.7 vs. 30.1%, P<0.001). In multivariable analyses, after stratification according to risk group categories, no difference in PSMs between RARP and ORP was observed for low-risk (odds ratio [OR] = 0.87, P = 0.46) and intermediate-risk patients (OR = 0.84, P = 0.19). Conversely, RARP was associated with lower odds of PSMs in high-risk patients (OR = 0.69, P = 0.04). Similar results were observed when our analyses were repeated after accounting for pathological characteristics, in patients treated between 2006 and 2014 and in a cohort of men treated by high-volume surgeons (all P≤ 0.03).Conclusions: The introduction of RARP at our institution led to a significant reduction in the risk of PSMs in patients with PCa with high-risk disease. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
40. Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center.
- Author
-
Scilipoti P, Longoni M, de Angelis M, Re C, Bertini A, Cannoletta D, Burgio G, Lucianò R, Rosiello G, Colombo R, Gandaglia G, Salonia A, Montorsi F, Briganti A, and Moschini M
- Abstract
Background: Induction followed by 1 year maintenance instillation of intravesical Bacillus Calmette-Guerin (BCG) is the standard treatment for intermediate-risk (IR) nonmuscle invasive bladder cancer (NMIBC) patients. Few data exist on the efficacy of Mitomycin C (MMC) instillation in this setting., Methods: We retrospectively analyzed 226 IR-NMIBC patients classified by the International Bladder Cancer Group (IBCG) and 250 IR-NMIBC intravescical treatment-naïve patients classified by the European Association of Urology (EAU). All patients received either a full induction course of BCG or 40 mg/40 ml MMC from 2012 to 2022. Optimal treatment was defined as 1-year maintenance for BCG and 11 monthly maintenance instillations for MMC. Kaplan-Meier analysis estimated recurrence-free survival (RFS) before and after inverse probability of treatment-weighting (IPTW) and progression-free survival (PFS). Multivariable Cox regression was used to evaluate difference in recurrence after adjustment for clinically relevant variables before and after IPTW., Results: Optimal BCG and MMC courses were administered to 21% of IR-IBCG and 23% of IR-EAU patients. At 4-years, patients treated with optimal MMC and BCG treatment had similar RFS and PFS in both EAU and IBCG groups. Patients receiving nonoptimal BCG compared to optimal MMC exhibited lower 4-year RFS after IPTW (82% vs. 68% in EAU and 82% vs. 65% in IBCG). At 4-year optimal MMC had greater PFS non optimal BCG. Optimal MMC treatment predicted recurrence in EAU (adjusted and weighted HR 0.33, 95% CI, 0.11-0.98) and IBCG (adjusted and weighted HR 0.29, 95% CI, 0.08-0.97) groups compared to nonoptimal BCG., Conclusions: Optimal 40 mg/40 ml MMC treatment was as effective as optimal BCG in IR-IBCG and IR-EAU NMIBC patients, reducing both recurrence and progression compared to nonoptimal BCG. MMC could be a valid first line alternative to BCG for both IR-EAU and IR-IBCG intravescical treatment-naïve patients, during BCG shortages., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?
- Author
-
Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, Shariat SF, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, and Moschini M
- Subjects
- Cystectomy methods, Female, Humans, Male, Retrospective Studies, Urinary Bladder pathology, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery
- Abstract
Objective: To compare the accuracy in detecting variant histologies (VH) at transurethral resection of bladder (TURB) and radical cystectomy (RC) specimen among tertiary referral centres, in order to investigate potential reasons of discrepancies from the pathological point of view., Patients and Methods: Clinical and histopathological data of TURB specimen and subsequent cystectomy specimen of 3,445 RC candidate patients have been retrospectively collected from 24 tertiary referral centres between 1980 and 2021. VH considered in the analysis were pure squamous cell carcinoma, urothelial carcinoma with squamous differentiation, pure adenocarcinoma, urothelial carcinoma with glandular differentiation, micropapillary bladder cancer (BCa), neuroendocrine BCa, and other variants. The degree of agreement between TURB and RC concerning the identification of VH was expressed as concordance, classified according to Cohen's kappa coefficient., Results: A VH was reported in 17% of TURB specimens, 45% of which were not confirmed in RC. The lowest concordance rate was reported for micropapillary BCa with 11 out of 18 (61%) centres reporting no agreement, whereas neuroendocrine BCa achieved the highest concordance rate with only 3 centres (17%) reporting no agreement. Our results shows that even among centres with the advantage of a referent uropathologist the micropapillary variant is characterized by scarce accuracy between TURB and RC. Differences in TURB specimen acquisition by the urologist and in sampling methods among different centres are the main limitations of the study., Conclusions: Accuracy of TURB in detecting VH is poor for certain VH, in particular for micropapillary BCa, with evident variation among centres. Novel diagnostic tools are required to better identify these VH and drive patients toward a personalized treatment., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
42. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists.
- Author
-
Lonati C, Mordasini L, Afferi L, De Cobelli O, Di Trapani E, Necchi A, Colombo R, Briganti A, Montorsi F, Simeone C, Zamboni S, Simone G, Karnes RJ, Marra G, Soria F, Gontero P, Shariat SF, Pradere B, Hendricksen K, Ammiwala M, Rink M, Poyet C, Krajewski W, Baumeister P, Mattei A, Moschini M, and Carando R
- Subjects
- Cystectomy methods, Female, Humans, Lymph Node Excision methods, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Lymph Nodes surgery, Male, Neoplasm Staging, Retrospective Studies, Urologists, Urinary Bladder Neoplasms diagnostic imaging, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery, Urology
- Abstract
Background: The preoperative lymph node (LN) staging of bladder cancer (BCa) addresses the subsequent therapeutic strategy and influences patient's prognosis. However, sparce evidence exists regarding the accuracy of conventional cross-sectional imaging, such as computed tomography or magnetic resonance imaging, in correctly detect LN status. We aimed to assess the diagnostic accuracy of conventional cross-sectional imaging in detecting preoperative LN involvement among BCa patients treated with radical cystectomy and pelvic lymph node dissection., Methods: We retrospectively analyzed data of 1,104 patients who underwent preoperative LN staging with computed tomography or magnetic resonance imaging and subsequent radical cystectomy with pelvic lymph node dissection for BCa between 1997 and 2017 at three tertiary referral centers. Patients receiving neoadjuvant chemotherapy were excluded. We assessed the concordance between clinical (cN) and pathological LN (pN) status, defined as the accuracy of imaging in detecting LN involvement using pathological specimen as reference; concordance was expressed according to Cohen's kappa coefficient. Location-based sub-analyses were performed, distinguishing among external iliac, intern iliac, obturator, common iliac, presacral and paraaortic LNs., Results: Among 870 cN0 patients, 68.9% were confirmed pN0 at pathological report; while among 234 cN+ patients, 50.5% were found with LN metastases at pathological specimen. Overall, conventional imaging showed slight concordance (64.9%) between cN and pN stages (sensitivity: 30%; specificity: 84%). At sub-analysis, no agreement between cN and pN status was found in each LN location, with the only exception of common iliac LNs with slight concordance (37.5%). Common iliac LNs achieved the highest sensitivity and positive likelihood ratio (15% and 2.4, respectively) compared to other LN locations., Conclusions: Overall, preoperative cross-sectional imaging exhibited a slight concordance between cN and pN status. Our location-based sub-analyses showed unsatisfactory results in each LN location- Thus, nomograms combining morphological patterns with serological and clinicopathological features are urgently required., Competing Interests: Conflict of interest disclosure None declared., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion does not increase hemorrhagic complications: results from a large multicentric cohort.
- Author
-
Albisinni S, Diamand R, Mjaess G, Assenmacher G, Assenmacher C, Loos S, Verhoest G, Holz S, Naudin M, Ploussard G, Mari A, Di Maida F, Minervini A, Aoun F, Tay A, Issa R, Roumiguié M, Bajeot AS, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Hendricksen K, Einerhand S, Sanchez-Salas R, Colomer A, Quackels T, Peltier A, Montorsi F, Briganti A, Pradere B, Moschini M, and Roumeguère T
- Subjects
- Aspirin adverse effects, Cystectomy adverse effects, Cystectomy methods, Female, Humans, Male, Platelet Aggregation Inhibitors adverse effects, Postoperative Complications epidemiology, Postoperative Complications etiology, Postoperative Complications surgery, Treatment Outcome, Robotic Surgical Procedures adverse effects, Robotic Surgical Procedures methods, Urinary Bladder Neoplasms complications, Urinary Diversion adverse effects, Urinary Diversion methods
- Abstract
Objectives: To evaluate whether continuing the antiplatelet drug acetylsalicylic acid≤100mg (ASA) during Robotic-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) increases the risk of peri-and postoperative hemorrhagic complications and overall morbidity. Indeed, guidelines recommend interrupting antiplatelet therapy before radical cystectomy; however, RARC with ICUD is associated to reduced estimated blood loss and blood transfusions compared to its open counterpart., Methods: Data from a multicentric European database were analyzed. All participating centers maintained a prospective database of patients undergoing RARC with ICUD. We identified patients receiving antiplatelet therapy by acetylsalicylic acid ≤100mg. Patients were divided into three groups: those not taking acetylsalicylic acid (no-ASA), those where ASA was continued perioperatively (c-ASA) and those where ASA was interrupted perioperatively (i-ASA). Estimated blood loss and peri-and post-operative transfusions were recorded. Hemorrhagic complications, ischemic, thrombotic and cardiac morbidity was recorded and classified using the Clavien-Dindo score by a senior urologist., Results: 640 patients were analyzed. Patients on acetylsalicylic acid were significantly older and had more comorbidities. No significant difference was found for estimated blood loss between no-ASA, c-ASA and i-ASA (280 vs. 300 vs. 200ml respectively; P = 0.09). Similarly, no significant difference was found for intraoperative (5% vs. 9% vs. 11%; P = 0.07) and postoperative transfusion rate (11% vs. 13% vs. 18%; P = 0.17). Higher ischemic complications were noted in the i-ASA group compared to no-ASA and c-ASA (4% vs. 0.6% vs. 1.4%; P = 0.03). On uni and multivariate logistic regression, continuing acetylsalicylic acid was not significantly associated to either major complications or post-operative transfusions., Conclusions: Peri-operative acetylsalicylic acid continuation in RARC with ICUD does not increase hemorrhagic complications. Interrupting acetylsalicylic acid peri-operatively may expose patients to a higher risk of ischemic events., Competing Interests: Conflict of interest The authors report no conflict of Interest., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
44. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer.
- Author
-
Moschini M, Arbelaez E, Cornelius J, Mattei A, Shariat SF, Dell Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, and Gallina A
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Lymph Nodes pathology, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Prognosis, Prospective Studies, Retrospective Studies, Urinary Bladder Neoplasms surgery, Cystectomy, Lymph Nodes surgery, Pelvic Neoplasms secondary, Pelvic Neoplasms surgery, Urinary Bladder Neoplasms pathology
- Abstract
Background: Pelvic lymph node dissection (PLND) has a diagnostic and therapeutic role during radical cystectomy in bladder cancer patients. However, at the time, no prospective data supports the value of extended PLND in improving survival expectances. We sought to describe incidence and location of node metastases in patients treated with extended and superextended PLND., Methods: We evaluated 653 contemporary patients with clinically nonmetastatic high risk nonmuscle invasive or muscle-invasive bladder cancer treated with radical cystectomy and extended or superextended PLND without neoadjuvant chemotherapy at a single tertiary referral center between 1990 and 2013. Limited PLND is defined as the removal of obturator and internal iliac nodes. Standard included also the external iliac nodes. Extended includes also common and presacral nodes. Finally, superextended PLND includes all the nodes removed along the inferior mesenteric artery. We evaluated incidence of pathologically node metastases. Logistic regression analyses evaluate preoperative and pathologic characteristics to the risk of harboring node metastases in the extended and superextended template., Results: Overall, 191 (29.3%) patients were found with pathologically node confirmed metastases. Of these, 56 (29.3%) patients were found with a single node metastasis, while 135 (70.7%) had multiple node metastases. The vast majority of patients were found with node metastases standard template (n = 172, 26.3%), on the other hand 30 (4.6%) and 21 (3.2%) patients had node metastases in extended and superextended templates, respectively. However, of these only 2 patients were found without concomitant lymph node metastases in the limited or standard templates. On multivariable analyses, cN+ status (odds ratio = 4.40, P<0.001) and cT3-4 vs. cT1-2 (odds ratio = 2.25, P<0.001) were associated with an increased risk of harboring node metastases in the extended or superextended template., Conclusions: We found that the majority of patients harbored node disease in the limited or standard node dissection pattern. On the other hand, only a minority of patient were found with a disease in extended or superextended template without harboring a concomitant node disease in the limited pattern., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
45. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
- Author
-
Dell'Oglio P, Bandini M, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Fossati N, Moschini M, Gandaglia G, Capitanio U, Briganti A, Graefen M, Montorsi F, Saad F, and Karakiewicz PI
- Subjects
- Adenocarcinoma economics, Adenocarcinoma secondary, Aged, 80 and over, Androgen Antagonists economics, Chemoradiotherapy economics, Female, Follow-Up Studies, Humans, Male, Prognosis, Prostatic Neoplasms economics, Prostatic Neoplasms pathology, Radiotherapy Dosage, Risk Factors, Survival Rate, Adenocarcinoma therapy, Androgen Antagonists therapeutic use, Chemoradiotherapy mortality, Prostatic Neoplasms therapy
- Abstract
Objective: Several randomized controlled trials have documented significant overall survival benefit in high metastatic risk prostate cancer (PCa) patients treated with combination of androgen deprivation therapy (ADT) at radiotherapy (RT) relative to RT alone. Unfortunately, elderly patients are either not included or are underrepresented in these trials. In consequence, the survival benefit of combination of ADT at RT in the elderly warrants detailed reassessment, including its cost., Methods: Between 1991 and 2009 within the Surveillance Epidemiology and End Results (SEER)-Medicare-linked database, we identified 3,692 patients aged 80 years or more with clinical T1-T2 PCa and WHO histological grade 3, or clinical T3-T4 PCa and any histological grade, treated with or without combination of ADT at RT. Competing risks analyses focused on cancer-specific mortality (CSM) and other-cause mortality, after accounting for confounders. All analyses were repeated in patients with no comorbidity and in most contemporary patients, treated between 2001 and 2009. Finally, we assessed median annual cost according to use of combination of ADT at RT, after adjusting for patient and tumor characteristics., Results: In competing-risks multivariable analyses, no statistically significant difference was observed in CSM and other-cause mortality between patients treated with or without combination of ADT at RT. Same results were recorded in subgroup analyses of patients with no comorbidity and in most contemporary patients. The median annual costs of $36,140 and of $47,510 were recorded, respectively in patients treated without and with ADT at RT., Conclusion: Our findings failed to confirm that combination of ADT at RT reduces CSM rates in high metastatic risk PCa patients aged 80 years or more. Moreover, combination of ADT at RT resulted in a significant cost increase, relative to RT alone., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
46. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
- Author
-
Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, and Shariat SF
- Subjects
- Aged, Disease-Free Survival, Follow-Up Studies, Humans, Kallikreins blood, Lymph Node Excision, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local blood, Prospective Studies, Prostate surgery, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms epidemiology, Prostatic Neoplasms surgery, Retrospective Studies, Treatment Outcome, Neoplasm Recurrence, Local epidemiology, Prostate pathology, Prostatectomy, Prostatic Neoplasms pathology
- Abstract
Aim: To assess the predictive value of TGP on biochemical recurrence (BCR) and its association with clinicopathological outcomes in a large, multicenter cohort of patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP)., Materials and Methods: Records of 6,041 patients who were treated with RP between 2000 and 2011 for clinically nonmetastatic PCa were, retrospectively, analyzed from prospectively collected datasets. BCR-free survival rates were assessed using univariable and multivariable cox-regression analyses., Results: Median patient age was 61 years (interquartile range [IQR]: 57-66) with a median preoperative prostrate specific antigen of 6ng/ml (IQR: 4-9). Overall, 28% of patients had Gleason score (GS) 6, 0.3% GS 6 + TGP, 33% GS 7 (3 + 4), 0.2% GS 7 (3 + 4) + TGP, 22% GS 7 (4 + 3), 0.2% GS 7 (4 + 3) + TGP, 0.1% GS 8 and 0.4% GS 9 or 10. Median follow-up was 45 months (IQR: 31-57). Harboring a TGP was associated with higher rates of positive surgical margins, lymphovascular invasion, extraprostatic extension, and seminal vesicle invasion than their counterparts within the same GS group as well as in the next higher GS group (all P ≤ 0.05). At 5 years post-RP, BCR estimates were 5% for patients with GS 6, 13% for patients with GS 6 + TGP, 6% for patients with GS 7 (3 + 4), 22% for patients with GS 7 (3 + 4) + TGP, 16% for patients with GS 7 (4 + 3), 41% for patients with GS 7 (4 + 3) + TGP, 38% for patients with GS 8 (4 + 4) and 46% for patients with GS 9 or 10. Patients harboring a TGP had higher BCR rates than the patients in the next higher GS group: GS 6 + TGP vs. GS 7 (3 + 4), HR = 1.6, P = 0.02 and GS 7 (3 + 4)+TGP vs. GS 7 (4 + 3), HR = 1.4, P = 0.03. Patients with a TGP in the GS 7 (4 + 3) group had comparable BCR rates as patients with GS = 8 (P = 0.4) and GS 9 to 10 (P = 0.2). On multivariable analysis that adjusted for the effects of preoperative prostrate specific antigen, nodal involvement, positive surgical margin, extraprostatic disease (pT3a), seminal vesicle invasion (pT3b) and different institution, harboring a TGP showed higher risk of developing BCR within the same GS group and comparable risk of developing BCR with the next higher GS group., Conclusion: Patients with TGP at RP have adverse clinicopathological features when compared to their counterparts in the same and the next higher GS group without TGP. Risk of developing BCR increases with the presence of TGP within the same GS group. This risk seems to be comparable between patients with TGP and their counterparts in the next higher GS group without TGP. Knowledge of TGP in RP specimens is likely to improve risk stratification, patient counseling and follow-up scheduling. Further prospective studies that control significant clinical endpoints such as metastasis and mortality are necessary for more significant predictions., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
47. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
- Author
-
Soria F, Moschini M, Abufaraj M, Wirth GJ, Foerster B, Gust KM, Özsoy M, Briganti A, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, and Shariat SF
- Subjects
- Administration, Intravesical, Aged, Anemia etiology, Chemotherapy, Adjuvant methods, Cystectomy methods, Disease Progression, Disease-Free Survival, Female, Humans, Male, Middle Aged, Muscles pathology, Neoplasm Grading, Neoplasm Recurrence, Local blood, Neoplasm Staging, Preoperative Period, Prognosis, Proportional Hazards Models, Retrospective Studies, Urinary Bladder pathology, Urinary Bladder Neoplasms blood, Urinary Bladder Neoplasms therapy, Anemia epidemiology, Neoplasm Recurrence, Local pathology, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology
- Abstract
Purpose: To evaluate the effect of preoperative anemia (PA) on oncological outcomes in a multicenter cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB) and adjuvant intravesical therapies. We hypothesize that PA represents a marker of disease aggressiveness and could be used to improve the discrimination of prognostic tools for the prediction of disease recurrence and progression., Methods: This multicenter retrospective study included 1,117 patients from 4 different centers. The presence of PA was assessed according to the World Health Organization classification as a preoperative hemoglobin level of≤13g/dl in men and≤12g/dl in women. PA evaluation was done at each institution, generally 1 to 3 days before surgery. Multivariable Cox regression models were performed to evaluate the prognostic effect of PA on survival outcomes., Results: Overall, 381 (34%) patients with NMIBC treated with TURB, had PA. Median follow-up for patients alive at last follow-up was 62.7 months (interquartile range: 25-110.7). On multivariable Cox regression analyses that accounted for the effect of standard clinicopathologic prognosticators, PA was independently associated with recurrence-free survival (P = 0.045) and progression-free survival (P = 0.01). Adding PA to a model for the prediction of disease recurrence and progression improved the discrimination of the prognostic models marginally from 69.8% to 70.3% and from 71.6% to 73.1%, respectively., Conclusions: PA was found in more than one-third of patients with NMIBC treated with TURB. PA was associated with poor oncological outcomes and was an independent predictor of intravesical disease recurrence and progression. However, the additional prognostic information provided by PA remains limited., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.